0001615774-17-002030.txt : 20170502 0001615774-17-002030.hdr.sgml : 20170502 20170502171652 ACCESSION NUMBER: 0001615774-17-002030 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170502 DATE AS OF CHANGE: 20170502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MISONIX INC CENTRAL INDEX KEY: 0000880432 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 112148932 STATE OF INCORPORATION: NY FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-10986 FILM NUMBER: 17806135 BUSINESS ADDRESS: STREET 1: 1938 NEW HIGHWAY CITY: FARMINGDALE STATE: NY ZIP: 11735 BUSINESS PHONE: (631) 694-9555 MAIL ADDRESS: STREET 1: 1938 NEW HIGHWAY CITY: FARMINGDALE STATE: NY ZIP: 11735 FORMER COMPANY: FORMER CONFORMED NAME: MEDSONIC INC DATE OF NAME CHANGE: 19930328 10-Q 1 s105975_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________.

Commission File Number: 1-10986

MISONIX, INC.

(Exact name of registrant as specified in its charter)

New York

(State or other jurisdiction of incorporation or
organization)

11-2148932

(IRS Employer Identification No.)

1938 New Highway

Farmingdale, New York

(Address of principal executive offices)

11735

(Zip code)

(631) 694-9555

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þ Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). þ Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨	Accelerated filer þ	Non-accelerated filer ¨	Smaller reporting company ¨
Emerging growth company ¨		(Do not check if a smaller reporting company)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes þ No

Indicate the number of shares outstanding of the issuer’s common stock as of the latest practicable date: As of April 28, 2017 there were 9,023,354 shares of the registrant’s common stock, $0.01 par value, outstanding.

MISONIX INC.

	Page
PART I — FINANCIAL INFORMATION

Item 1. Financial Statements	3

Consolidated Balance Sheets at March 31, 2017 (Unaudited) and June 30, 2016	3

Consolidated Statements of Operations for the Three and Nine Months ended March 31, 2017 and 2016 (Unaudited)	4

Consolidated Statement of Shareholders’ Equity for the Nine Months ended March 31, 2017 (Unaudited)	5

Consolidated Statements of Cash Flows for the Nine Months ended March 31, 2017 and 2016 (Unaudited)	6

Notes to Consolidated Financial Statements (Unaudited)	7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3. Quantitative and Qualitative Disclosures About Market Risk	19

Item 4. Controls and Procedures	19

PART II — OTHER INFORMATION

Item 1. Legal Proceedings	23

Item 1A. Risk Factors	24

Item 6. Exhibits	24

Signatures	25

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

Misonix, Inc. and Subsidiaries
Consolidated Balance Sheets

	March 31,			June 30,
	2017			2016
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	11,856,503		$	9,049,327
Accounts receivable, less allowance for doubtful accounts of $96,868 and $96,868, respectively		4,357,156			3,869,427
Inventories, net		4,909,415			5,822,935
Prepaid expenses and other current assets		664,249			530,564
Total current assets		21,787,323			19,272,253

Property, plant and equipment, net of accumulated amortization and depreciation of $7,610,152 and $6,976,282, respectively		3,413,116			2,492,815
Patents, net of accumulated amortization of $965,996 and $885,394, respectively		710,070			604,916
Goodwill		1,701,094			1,701,094
Intangible and other assets		300,341			266,603
Deferred income tax		3,581,551			3,394,690
Total assets	$	31,493,495		$	27,732,371

Liabilities and shareholders' equity
Current liabilities:
Accounts payable	$	1,433,608		$	1,402,797
Accrued expenses and other current liabilities		1,994,387			1,887,337
Total current liabilities		3,427,995			3,290,134

Deferred lease liability		9,331			9,262
Deferred income		17,737			31,685
Total liabilities		3,455,063			3,331,081

Commitments and contingencies (Footnote 9)

Shareholders' equity:
Common stock, $.01 par value-shares authorized 20,000,000; 9,162,203 and 7,948,234 shares issued and 9,023,354 and 7,809,385 outstanding in each period, respectively		91,622			79,482
Additional paid-in capital		37,410,034			32,502,521
Accumulated deficit		(8,363,872	)		(7,081,361	)
Treasury stock, at cost, 138,849 shares in each period		(1,099,352	)		(1,099,352	)
Total shareholders' equity		28,038,432			24,401,290
Total liabilities and shareholders' equity	$	31,493,495		$	27,732,371

See Accompanying Notes to Consolidated Financial Statements.

Misonix, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)

	For the three months ended						For the nine months ended
	March 31,						March 31,
	2017			2016			2017			2016

Net sales	$	7,177,763		$	5,426,147		$	19,379,768		$	16,716,487
Cost of goods sold, exclusive of depreciation from consigned product		2,112,099			1,859,749			5,842,778			5,578,349
Gross profit		5,065,664			3,566,398			13,536,990			11,138,138

Operating expenses:
Selling expenses		3,587,859			3,319,385			10,184,680			8,967,352
General and administrative expenses		2,484,962			1,515,559			6,504,202			4,994,569
Research and development expenses		465,863			548,278			1,398,311			1,340,339
Total operating expenses		6,538,684			5,383,222			18,087,193			15,302,260
Loss from operations		(1,473,020	)		(1,816,824	)		(4,550,203	)		(4,164,122	)

Other income (expense):
Interest income		18			19			56			63
Royalty income and license fees		953,235			963,025			2,846,351			2,969,557
Other		(6,940	)		(5,464	)		(15,576	)		(16,898	)
Total other income		946,313			957,580			2,830,831			2,952,722

Loss from operations before income taxes		(526,707	)		(859,244	)		(1,719,372	)		(1,211,400	)

Income tax benefit		(219,000	)		(15,000	)		(275,000	)		(322,000	)

Loss from continuing operations		(307,707	)		(844,244	)		(1,444,372	)		(889,400	)
Discontinued operations:
Income from discontinued operations net of tax expense of $88,139 and $85,000 respectively		161,861			165,000			161,861			165,000
Net income from discontinied operations		161,861			165,000			161,861			165,000
Net loss from total operations		(145,846	)		(679,244	)		(1,282,511	)		(724,400	)

Net loss per share - Basic continuing Operations	$	(0.04	)	$	(0.11	)	$	(0.17	)	$	(0.11	)
Net loss per share - Diluted continuing operations	$	(0.04	)	$	(0.11	)	$	(0.17	)	$	(0.11	)

Net income per share - Basic discontinued operations	$	0.02		$	0.02		$	0.02		$	0.02
Net income per share - Diluted discontinued operations	$	0.02		$	0.02		$	0.02		$	0.02

Net loss per share - Basic	$	(0.02	)	$	(0.09	)	$	(0.16	)	$	(0.09	)
Net lossper share - Diluted	$	(0.02	)	$	(0.09	)	$	(0.16	)	$	(0.09	)

Weighted average shares - Basic		8,613,354			7,789,174			8,263,343			7,772,761
Weighted average shares - Diluted		8,613,354			7,789,174			8,263,343			7,772,761

See Accompanying Notes to Consolidated Financial Statements.

Misonix, Inc. and Subsidiaries
Consolidated Statement of Shareholders’ Equity
(Unaudited)

	For the Nine Months Ended March 31, 2017
	Common Stock,
	$.01 Par Value				Treasury Stock						Additional						Total
	Number				Number						paid-in			Accumulated			shareholders'
	of shares		Amount		of shares			Amount			capital			deficit			equity
Balance, June 30, 2016		7,948,234	$	79,482		(138,849	)	$	(1,099,352	)	$	32,502,521		$	(7,081,361	)	$	24,401,290
Net loss		-		-		-			-			-			(1,282,511	)		(1,282,511	)
Sale of common stock		761,469		7,615		-			-			3,992,385			-			4,000,000
Issuance of restricted stock		400,000		4,000		-			-			(4,000	)		-			-
Proceeds from exercise of options		52,500		525		-			-			302,922			-			303,447
Stock-based compensation						-			-			616,206			-			616,206

Balance, March 31, 2017		9,162,203	$	91,622		(138,849	)	$	(1,099,352	)	$	37,410,034		$	(8,363,872	)	$	28,038,432

See Accompanying Notes to Consolidated Financial Statements.

Misonix, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)

	For the nine months ended
	March 31,
	2017			2016
Operating activities
Net loss from continuing operations	$	(1,444,372	)	$	(889,400	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization and other non-cash items		763,434			1,271,864
Deferred income tax benefit		(186,861	)		(260,000	)
Stock-based compensation		616,206			1,175,165
Deferred income		(13,948	)		(20,852	)
Deferred lease liability		69			6,947
Changes in operating assets and liabilities:
Accounts receivable		(487,729	)		379,689
Inventories		(449,986	)		(2,623,620	)
Prepaid expenses and other assets		(167,423	)		(282,221	)
Accounts payable and accrued expenses		137,861			141,624
Net cash used in operating activities		(1,232,749	)		(1,100,804	)

Investing activities
Acquisition of property, plant and equipment, net of disposals		(239,627	)		(410,561	)
Acquisition of patents		(185,756	)		(71,541	)
Net cash used in investing activities		(425,383	)		(482,102	)

Financing activities
Proceeds from the sale of common stock		4,000,000			-
Proceeds from exercise of stock options		303,447			151,247
Net cash provided by financing activities		4,303,447			151,247

Cash flows from discontinued operations
Net cash provided by investing activities		161,861			165,000
Net cash provided by discontinued operations		161,861			165,000

Net increase / (decrease) in cash and cash equivalents		2,807,176			(1,266,659	)
Cash and cash equivalents at beginning of period		9,049,327			9,623,749
Cash and cash equivalents at end of period	$	11,856,503		$	8,357,090

Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	9,866		$	141,120
Capitalization of consigned product	$	1,363,506		$	1,017,506

See Accompanying Notes to Consolidated Financial Statements.

MISONIX, INC. and Subsidiaries

Notes to Consolidated Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

1. Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies

Basis of Presentation

These consolidated financial statements of Misonix, Inc. (“Misonix” or the “Company”) include the accounts of Misonix and its 100% owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. As such, they should be read with reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which provides a more complete explanation of the Company’s accounting policies, financial position, operating results, business properties and other matters. In the opinion of management, these financial statements reflect all adjustments considered necessary for a fair statement of interim results.

Reclassifications

Certain expenses on the Statement of Operations have been reclassified to be consistent with the current year presentation. Historically, the Company had recorded stock compensation expense and bonus expense predominantly within general and administrative expenses. The Company has reclassified the prior years’ presentation to allocate certain of these costs to cost of goods sold, selling expenses and research and development expenses, which is consistent with the classification being used in fiscal 2017. This reclassification had no impact on the Company’s presentation of operating income (loss) and the gross profit impact was not material.

Organization and Business

Misonix designs, manufactures, develops and markets therapeutic ultrasonic devices. These products are used for precise bone sculpting, removal of soft tumors, and tissue debridement in the fields of orthopedic surgery, plastic surgery, neurosurgery, podiatry and vascular surgery. In the United States, the Company sells its products through a network of commissioned agents assisted by Company personnel. Outside of the United States, the Company sells to distributors who then resell the product to hospitals. The Company operates as one business segment.

High Intensity Focused Ultrasound Technology

The Company sold its rights to the high intensity focused ultrasound technology to SonaCare Medical, LLC (“SonaCare”) in May 2010. The Company may receive up to approximately $5.8 million in payment for the sale. SonaCare will pay the Company 7% of the gross revenues received from its sales of the (i) prostate product in Europe and (ii) kidney and liver products worldwide, until the Company has received payments of $3 million, and thereafter 5% of the gross revenues, up to an aggregate payment of $5.8 million, all subject to a minimum annual royalty of $250,000. Cumulative payments through March 31, 2017 were $1,504,788. Payments are generally received once per year, in the Company’s third fiscal quarter. For the three months ended March 31, 2017 and 2016, the Company received a royalty of $250,000 in each quarter, which has been recorded in discontinued operations.

Major Customers and Concentration of Credit Risk

Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. (“Cicel”) of $0 and $1,337,277 for the nine months ended March 31, 2017 and 2016, respectively, representing 8.0% of sales for 2016. There were no accounts receivable from Cicel at March 31, 2017 and June 30, 2016. The Company terminated its agreement with Cicel in the first quarter of fiscal 2017.

For the three months ended March 31, 2017, one international distributor accounted for approximately 10% of sales for the quarter. In addition, this same customer had outstanding accounts receivable at March 31, 2017 of $369,463.

Total royalties from Medtronic Minimally Invasive Therapies (“MMIT”) related to their sales of the Company’s ultrasonic cutting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $2,838,487 and $2,930,240, for the nine months ended March 31, 2017 and 2016, respectively. Accounts receivable from MMIT royalties were approximately $953,000 and $973,000 at March 31, 2017 and June 30, 2016, respectively. The license agreement with MMIT expires in August 2017.

At March 31, 2017 and June 30, 2016, the Company’s accounts receivable with customers outside the United States were approximately $762,000 and $768,000, respectively, none of which is over 90 days.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for, but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and related valuation allowances, and stock-based compensation. Actual results could differ from those estimates.

Loss per Common Share

Diluted EPS for the three and nine months ended March 31, 2017 and March 31, 2016 as presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. Accordingly, excluded from the calculation of diluted EPS are outstanding options to purchase 145,750 and 512,750 shares of common stock for the three and nine months ended March 31, 2017, and options to purchase 844,250 and 486,000 shares of common stock for the three and nine months ended March 31, 2016.

Recent Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will apply this guidance to applicable impairment tests after January 1, 2017.

In February 2016, the FASB issued guidance on lease accounting requiring lessees to recognize a right-of-use asset and a lease liability for long-term leases. The liability will be equal to the present value of lease payments. This guidance must be applied using a modified retrospective transition approach to all annual and interim periods presented and is effective for the Company beginning in fiscal 2019. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.

In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes (Topic740)”. The amendments in this ASU require deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments eliminate the guidance in Topic 740 that requires an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount in a classified statement of financial position. The Company adopted ASU 2015-17 as of March 31, 2016 on a prospective basis in order to simplify the balance sheet classification of deferred taxes.

In May 2014, the FASB issued guidance on revenue from contracts with customers. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved, in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. This guidance permits the use of either the retrospective or cumulative effect transition method and is effective for the Company beginning in 2019; early adoption is permitted beginning in 2018. The Company has not yet selected a transition method and is currently evaluating the impact of the guidance on the Company's financial condition, results of operations and related disclosures. The FASB has also issued the following additional guidance clarifying certain issues on revenue from contracts with customers: Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients and Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

2. Fair Value of Financial Instruments

We follow a three-level fair value hierarchy that prioritizes the inputs to measure fair value. This hierarchy requires entities to maximize the use of "observable inputs" and minimize the use of "unobservable inputs." The three levels of inputs used to measure fair value are as follows:

Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets as of the measurement date.

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs that reflect assumptions that market participants would use in pricing an asset or liability.

At March 31, 2017 and June 30, 2016, all of our cash, trade accounts receivable and trade accounts payable were short term in nature, and their carrying amounts approximate fair value.

3. Inventories

Inventories are summarized as follows:

	March 31,		June 30,
	2017		2016
Raw material	$	2,481,557	$	3,102,175
Work-in-process		708,593		854,631
Finished goods		3,004,743		3,101,234
		6,194,893		7,058,040
Less valuation reserve		1,285,478		1,235,105
	$	4,909,415	$	5,822,935

4. Property, Plant and Equipment

Depreciation and amortization of property, plant and equipment was $253,515 and $345,355 for the three months ended March 31, 2017 and 2016, respectively, and was $682,832 and $982,984 for the nine months ended March 31, 2017 and 2016, respectively. Inventory items included in property, plant and equipment are depreciated using the straight line method over estimated useful lives of 3 to 5 years. Depreciation of generators which are consigned to customers is expensed over a 5 year period during the nine months ended March 31, 2017 and is expensed over a 3 year period for the nine months ended March 31, 2016, and depreciation is charged to selling expenses. The impact of this change in accounting estimate was a reduction in expense of approximately $533,000 for the nine months ended March 31, 2017, compared to what the expense would have been without this change.

5. Goodwill

Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or products. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long term rate of growth for the Company’s business, the useful lives over which cash flows will occur and determination of the Company’s weighted average cost of capital. The Company primarily utilizes the Company’s market capitalization and a discontinued cash flow model in determining the fair value which consists of Level 3 inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. The Company completed its annual goodwill impairment tests for fiscal 2016 and 2015 as of June 30 of each year. No impairment of goodwill was deemed to exist in fiscal 2016 and 2015.

6. Patents

The costs of acquiring or processing patents are capitalized at cost. These amounts are being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Patents totaled $710,070 and $604,916 at March 31, 2017 and June 30, 2016, respectively. Amortization expense for the three months ended March 31, 2017 and 2016 was $27,877and $23,090, respectively, and for the nine months ended March 31, 2017 and 2016 was $80,602 and $69,897, respectively.

The following is a schedule of estimated future patent amortization expense as of March 31, 2017:

2017	$	28,239
2018		110,790
2019		102,484
2020		79,055
2021		72,884
Thereafter		316,618
	$	710,070

7. Accrued Expenses and Other Current Liabilities

The following summarizes accrued expenses and other current liabilities:

	March 31,		June 30,
	2017		2016

Accrued payroll, payroll taxes and vacation		676,882		648,705
Accrued bonus		300,000		300,000
Accrued commissions		429,000		433,000
Professional fees		228,584		256,130
Deferred income		29,491		20,655
Severance		99,859		-
Other		230,571		228,847

	$	1,994,387	$	1,887,337

8. Stock-Based Compensation Plans

Stock Option Awards

For the three and nine months ended March 31, 2017, the compensation cost that has been charged against income for the Company’s stock option plans was $532,341 and $616,206, respectively, which in the nine month period included a charge to modify certain stock options of $81,765 and a reversal of stock compensation from prior periods due to forfeitures of unvested options of $616,239. For the three and nine months ended March 31, 2016, compensation cost that has been charged against income for the Company’s stock option plans was $446,172 and $1,175,000, respectively. As of March 31, 2017, there was approximately $2,771,938 of total unrecognized compensation cost related to non-vested share-based compensation arrangements to be recognized over a weighted-average period of 2.8 years.

Stock options typically expire 10 years from the date of grant and vest over service periods, which typically are 4 years. All options are granted at fair market value, as defined in the applicable plans.

The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. The expected volatility represents the historical price changes of the Company’s stock over a period equal to that of the expected term of the option. The Company uses the simplified method for determining the option term. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The expected dividend yield is based upon historical and projected dividends. The Company has historically not paid dividends, and is not expected to do so in the near term.

The weighted average fair value at date of grant for options granted during the nine months ended March 31, 2017 and 2016 was $4.46 and $4.23, respectively. There were options to purchase 327,500 shares granted during the nine months ended March 31, 2017. The fair value was estimated based on the weighted average assumptions of:

	For nine months ended March 31,
	2017			2016
Risk-free interest rates		1.80	%		1.71	%
Expected option life in years		6.25			6.25
Expected stock price volatility		54.68	%		55.41	%
Expected dividend yield		0	%		0	%

A summary of option activity under the Company’s equity plans as of March 31, 2017, and changes during the nine months ended March 31, 2017 is presented below:

	Outstanding Shares			Average Exercise Price		Aggregate Instrinsic Value
Vested and exercisable at June 30, 2016		1,790,224		$	6.38	$	1,675,072
Granted		327,500		$	8.34
Exercised		(52,500	)	$	5.78
Forfeited		(376,625	)	$	8.24
Expired		(2,700	)	$	3.45
Outstanding as of March 31, 2017		1,685,899		$	6.37	$	9,324,182
Vested and exercisable at March 31, 2017		980,774		$	4.63	$	7,097,409

The total fair value of shares vested during the nine months ended March 31, 2017 was $1,055,434. The number and weighted-average grant-date fair value of non-vested stock options at the beginning of fiscal 2017 was 976,875 and $4.81, respectively. The number and weighted-average grant-date fair value of stock options which vested during the nine months ended March 31, 2017 was 224,250 and $4.71, respectively.

Restricted Stock Awards

On December 15, 2016, the Company issued 400,000 shares of restricted stock to its Chief Executive Officer. These awards vest over a period of up to five years, subject to meeting certain service, performance and market conditions. These awards were valued at approximately $3.4 million and compensation expense recorded in the three and nine months ended March 31, 2017 was $224,498 and $265,063, respectively.

9. Commitments and Contingencies

Leases

The Company has entered into several non-cancellable operating leases for the rental of certain manufacturing and office space, equipment and automobiles expiring in various years through 2021. The principal building lease provides for a monthly rental of approximately $26,000. The Company also leases certain office equipment and automobiles under operating leases expiring through fiscal 2018.

Class Action Securities Litigation

On September 19, 2016, Richard Scalfani, an individual shareholder of Misonix, filed a lawsuit against the Company and its former CEO and CFO in the U.S. District Court for the Eastern District of New York, alleging violations of the federal securities laws. The complaint alleges that the Company’s stock price was artificially inflated between November 5, 2015 and September 14, 2016 as a result of alleged false and misleading statements in the Company’s securities filings concerning the Company’s business, operations, and prospects and the Company’s internal control over financial reporting. Scalfani filed the action seeking to represent a putative class of all persons (other than defendants, officers and directors of the Company, and their affiliates) who purchased publicly traded Misonix securities between November 5, 2015 and September 14, 2016. Scalfani seeks an unspecified amount of damages for himself and for the putative class under the federal securities laws. On March 24, 2017, the Court appointed Scalfani and another individual Misonix shareholder, Tracey Angiuoli, as lead plaintiffs for purposes of pursuing the action on behalf of the putative class. The Company believes it has various legal and factual defenses to the allegations in the complaint, and intends to vigorously defend the action. The case is at its earliest stages; there has been no discovery and there is no trial date. The Company is not able to estimate the amount of potential loss it may recognize, if any, from this claim. The Company believes that its insurance coverage is sufficient to cover a potential loss, after payment of the policy retention of $250,000.

Former Chinese Distributor - FCPA

For several months, with the assistance of outside counsel, the Company conducted a voluntary investigation into the business practices of the independent Chinese entity that previously distributed its products in China and the Company’s knowledge of those business practices, which may have implications under the FCPA, as well as into various internal controls issues identified during the investigation.

On September 27, 2016 and September 28, 2016, we voluntarily contacted the SEC and the DOJ, respectively, to advise both agencies of these potential issues. The Company has provided and will continue to provide documents and other information to the SEC and the DOJ, and is cooperating fully with these agencies in their investigations of these matters.

Although the Company’s investigation is complete, additional issues or facts could arise which may expand the scope or severity of the potential violations. The Company has no current information derived from the investigation or otherwise to suggest that its previously reported financial statements and results are incorrect.

At this stage, the Company is unable to predict what, if any, action the DOJ or the SEC may take or what, if any, penalties or remedial measures these agencies may seek. Nor can the Company predict the impact on the Company as a result of these matters, which may include the imposition of fines, civil and criminal penalties, which are not currently estimable, as well as equitable remedies, including disgorgement of any profits earned from improper conduct and injunctive relief, limitations on the Company’s conduct, and the imposition of a compliance monitor. The DOJ and the SEC periodically have based the amount of a penalty or disgorgement in connection with an FCPA action, at least in part, on the amount of profits that a company obtained from the business in which the violations of the FCPA occurred. During its distributorship relationship with the prior Chinese distributor from 2010 through 2016, the Company generated sales of approximately $8 million from the relationship.

Further, the Company may suffer other civil penalties or adverse impacts, including lawsuits by private litigants in addition to the lawsuit that has already been filed, or investigations and fines imposed by local authorities. The investigative costs to date are approximately $2.1 million, of which approximately $2.0 million was charged to general and administrative expenses during the nine months ended March 31, 2017. Investigative costs for the three months ended March 31, 2017 were approximately $650,000.

Former Chinese Distributor – Litigation

On April 5, 2017, the Company’s former distributor in China, Cicel (Beijing) Science & Technology Co., Ltd., filed a lawsuit against the Company and certain officers and directors of the Company in the United States District Court for the Eastern District of New York, alleging that the Company improperly terminated its contract with the former distributor. The complaint, which seeks various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, asserts various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. The Company believes it has various legal and factual defenses to the allegations in the complaint, and intends to vigorously defend the action. The case is at its earliest stages; there has been no discovery and there is no trial date.

10. Related Party Transactions

Applied BioSurgical, a company owned by the brother of the Company’s Chief Executive Officer, Stavros G. Vizirgianakis, is an independent distributor for the Company outside of the United States.

Set forth below is a table showing the Company’s net sales for the nine months ended March 31 and accounts receivable at March 31 for the indicated time periods below with Applied BioSurgical:

	2017		2016

Sales	$	367,592	$	349,490
Accounts receivable	$	104,678	$	212,981

On October 25, 2016, the Company sold 761,469 shares of Common Stock in a private placement to Stavros G. Vizirgianakis, the Company’s current Chief Executive Officer, at a price per share of $5.253, representing total cash proceeds to the Company of approximately $4.0 million.

11. Income Taxes

For the three months ended March 31, 2017 and 2016, the Company recorded an income tax benefit from continuing operations of $219,000 and $15,000, respectively, and for the nine months ended March 31, 2017 and 2016, the Company recorded an income tax benefit from continuing operations of $275,000 and $322,000, respectively.

For the nine months ended March 31, 2017 and 2016, the effective rate of 16.0% and 26.6%, respectively, on continuing operations varied from the U.S. federal statutory rate primarily due to permanent book tax differences relating principally to stock compensation expense and tax credits.

As of March 31, 2017 and June 30, 2016, the Company has no material unrecognized tax benefits or accrued interest and penalties.

12. Licensing Agreements for Medical Technology

In October 1996, the Company entered into a License Agreement with MMIT expiring August 2017, covering the further development and commercial exploitation of the Company's medical technology relating to laparoscopic products, which uses high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery. The MMIT license provides for exclusive worldwide marketing and sales rights for this technology. The Company receives a 5% royalty on sales of these products by MMIT. Royalties from this license agreement were $953,235 and $956,947 for the three months ended March 31, 2017 and 2016, respectively, and were $2,838,487 and $2,932,240 for the nine months ended March 31, 2017 and 2016, respectively.

13. Segment Reporting

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker (“CODM") in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company has concluded that its Chief Executive Officer is the CODM as he is the ultimate decision maker for key operating decisions, determining the allocation of resources and assessing the financial performance of the Company. These decisions, allocations and assessments are performed by the CODM using consolidated financial information. Consolidated financial information is utilized by the CODM as the Company's current product offering primarily consists of minimally invasive therapeutic ultrasonic medical devices. The Company's products are relatively consistent and manufacturing is centralized and consistent across product offerings. Based on these factors, key operating decisions and resource allocations are made by the CODM using consolidated financial data and as such the Company has concluded that it operates as one segment.

Worldwide revenue for the Company's products is categorized as follows:

	For the Nine Months Ended
	March 31
	2017		2016

Domestic	$	12,019,103	$	9,324,928
International		7,360,665		7,391,559
Total	$	19,379,768	$	16,716,487

Substantially all of the Company’s long-lived assets are located in the United States.

14. Severance

On August 26, 2016, the Company and the Company’s former Chief Executive Officer, Michael McManus (“McManus”) entered into a retirement agreement and general release (the “Retirement Agreement”). Pursuant to the Retirement Agreement, on September 2, 2016 Mr. McManus resigned as a Director and the Chairman of the Board of Directors of the Company and retired as President and Chief Executive Officer of the Company. Pursuant to the Retirement Agreement, the Company agreed to (i) pay Mr. McManus’ salary through June 30, 2017 at the then current level; (ii) continue to pay premiums for Mr. McManus’ and his dependents’ coverage under the Company’s medical, dental, vision, hospitalization, long term care and life insurance coverage through June 30, 2017 at the then current levels upon timely election by Mr. McManus under the law informally known as COBRA; and (iii) extend the exercisability of previously granted and then currently vested options to purchase shares of Common Stock through June 30, 2017. In addition, Mr. McManus had continued use of the vehicle provided him pursuant to his prior employment agreement through December 31, 2016. In connection with this Retirement Agreement, the Company recorded a charge of $330,000 during the quarter ended September 30, 2016 to accrue for the cash portion of these benefits, which will be paid during the period ending June 30, 2017. In addition, the Company recorded a non-cash compensation expense of $61,000 in connection with the modification of the terms of his vested stock options, and recorded a reduction in non-cash compensation expense of $596,000 relating to the forfeiture of his unvested stock options.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations of Misonix and its subsidiaries, which we refer to as the “Company”, “Misonix”, “we”, “our” and “us”, should be read in conjunction with the accompanying unaudited financial statements included in Part I – Item 1 “Financial Statements” of this Report and Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on February 9, 2017, for the fiscal year ended June 30, 2016 (“2016 Form 10-K”). Item 7 of the 2016 Form 10-K describes the application of our critical accounting policies, for which there have been no significant changes as of March 31, 2017.

Forward Looking Statements

With the exception of historical information contained in this Form 10-Q, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. We cannot guarantee that any forward looking statements will be accurate, although we believe that we have been reasonable in our expectations and assumptions. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevance, risks involved in introducing and marketing new products, regulatory compliance, potential acquisitions, consumer and industry acceptance, litigation and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in our business lines, and other factors discussed in the 2016 Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We disclaim any obligation to update any forward-looking statements.

Overview

In the United States, the Company is taking a more aggressive approach to taking market share, expanding the market and increasing its share of recurring disposable revenue by using a consignment model, whereby the Company will consign the equipment (which is defined as a generator, hand pieces and accessories) (the “Equipment”) and sell to customers higher margin disposable, single use items (the “Consumables”) on a recurring basis. Title remains with the Company with respect to consigned Equipment, which is depreciated and charged to selling expenses over a five year period beginning in fiscal 2017, and a three year period in fiscal 2016. Outside of the United States, the Company has principally not yet adopted a consignment model. The Company’s overall goal is to increase the utilization rate of Equipment which will increase the total number of procedures and maximize the sale of Consumables to our customers, with the goal of becoming the standard of care in the various areas we focus on.

Results of Operations

The following discussion and analysis provides information which the Company's management believes is relevant to an assessment and understanding of the Company's results of operations and financial condition. This discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere herein. Unless otherwise specified, this discussion relates solely to the Company's continuing operations.

All of the Company's sales have been derived from the sale of medical device products, which include manufacture and distribution of ultrasonic medical device products.

Three months ended March 31, 2017 and 2016

Our sales by category for the three months ended March 31, 2017 and 2016 are as follows:

	For the Three Months Ended
	March 31,				Net Change
	2017		2016		$			%

Total
Consumables	$	5,281,454	$	4,131,620	$	1,149,834			27.8	%
Equipment		1,896,309		1,294,527		601,782			46.5	%
Total	$	7,177,763	$	5,426,147	$	1,751,616			32.3	%

Domestic
Consumables	$	3,736,960	$	2,684,940	$	1,052,020			39.2	%
Equipment		278,348		369,877		(91,529	)		-24.7	%
Total	$	4,015,308	$	3,054,817	$	960,491			31.4	%

International
Consumables	$	1,544,494	$	1,446,680	$	97,814			6.8	%
Equipment		1,617,961		924,650		693,311			75.0	%
Total	$	3,162,455	$	2,371,330	$	791,125			33.4	%

Net sales

Net sales increased 32.3% or $1,751,616 to $7,117,763 in the third quarter of fiscal 2017, from $5,426,147 in fiscal 2016. Consumable sales in the United States increased 39.2%, or $1,052,020 for the quarter, in part due to the strength in the Company’s domestic consumables business, along with increased international equipment sales. International sales grew 33.4% during the third quarter, largely resulting from initial shipments to the Company’s new Chinese distributor of $739,285.

Gross profit

Gross profit in the third quarter of fiscal 2017 was 70.6% of sales, which increased from 65.7% in the third quarter of fiscal 2016. The increase resulted from a stronger mix of Consumables revenue which carries a higher gross profit margin than Equipment revenue.

Selling expenses

Selling expenses increased by $268,474, or 8.1% to $3,587,859 in the third quarter of fiscal 2017 from $3,319,385 in the prior year period. The increase is principally related to higher distributor commissions resulting from the sales increase, along with higher salary and benefit expenses. The Company continues to invest in sales and marketing in order to gain market share. The Company’s strategy to leverage its existing distributor network with product specialists domestically resulted in part in domestic sales growing by 31.4% during the third quarter. This quarterly expense increase was partially offset by a decrease in depreciation of consigned units of $114,000, resulting from a change in accounting estimate to depreciate these units over five years in fiscal 2017 compared with three years in fiscal 2016.

General and administrative expenses

General and administrative expenses increased by $969,403, or 64.0% to $2,484,962 in the third quarter of fiscal 2017 from $1,515,559 in the prior year period. The increase resulted principally from increased legal and accounting fees of approximately $700,000 relating to the internal investigation described in Part II – Item 1 “Legal Proceedings” below (“the Investigation”).

Research and development expenses

Research and development expenses decreased by $82,415, or 15.0% to $465,863 in the third quarter of fiscal 2017 from $548,278 in the prior year period. The decrease is due to lower product development costs during the quarter.

Other income (expense)

Other income decreased $11,267 to $946,313 in the third quarter of fiscal 2017 from $957,580 in the prior year period. The decrease is related to lower royalty income from MMIT. This royalty agreement expires in August 2017.

Income taxes

For the three months ended March 31, 2017 and 2016, the Company recorded an income tax benefit from continuing operations of $219,000 and $15,000, respectively. For the three months ended March 31, 2017 and 2016, the effective rate of 41.6% and 1.7%, respectively, on continuing operations varied from the U.S. federal statutory rate due to changes in the Company’s projected pretax book income.

Nine months ended March 31, 2017 and 2016

Our sales by category for the nine months ended March 31, 2017 and 2016 are as follows:

	For the Nine Months Ended
	March 31,				Net Change
	2017		2016		$			%

Total
Consumables	$	14,734,534	$	11,437,613	$	3,296,921			28.8	%
Equipment		4,645,234		5,278,874		(633,640	)		-12.0	%
Total	$	19,379,768	$	16,716,487	$	2,663,281			15.9	%

Domestic
Consumables	$	10,899,498	$	7,971,686	$	2,927,812			36.7	%
Equipment		1,119,605		1,353,242		(233,637	)		-17.3	%
Total	$	12,019,103	$	9,324,928	$	2,694,175			28.9	%

International
Consumables	$	3,835,036	$	3,465,927	$	369,109			10.6	%
Equipment		3,525,629		3,925,632		(400,003	)		-10.2	%
Total	$	7,360,665	$	7,391,559	$	(30,894	)		-0.4	%

Net sales

Net sales increased 15.9% or $2,663,281 to $19,379,768 in the first nine months of fiscal 2017, from $16,716,487 in the prior year period. Consumable sales in the United States increased 36.7%, or $2,927,812 for the period, in part due to the Company’s continued investment in its sales team and marketing efforts. Sales of Consumables have increased to 76.0% of sales in the first nine months of fiscal 2017 compared with 68.4% in the same period in fiscal 2016. Sales to customers in the United States increased to 62.0% of sales in the first nine months of fiscal 2017, compared with 58.8% in in the same period of fiscal 2016. International sales were $7,360,665 million for the first nine months of fiscal 2017, approximately even with the $7,391,559 recorded in the same period of the prior year. During the first quarter of fiscal 2017, the Company terminated its relationship with its Chinese distributor, which was its largest customer. During the third quarter of fiscal 2017, the Company executed an agreement with a new Chinese distributor, with initial shipments commencing in March 2017.

Gross profit

Gross profit in the first nine months of fiscal 2017 was 69.9% of sales, which increased from 66.6% in the prior year period. The increase resulted from a stronger mix of Consumables revenue which carries a higher gross profit margin than Equipment revenue.

Selling expenses

Selling expenses increased by $1,217,328, or 13.6% to $10,184,680 in the first nine months of fiscal 2017 from $8,967,352 in the prior year period. The increase is principally related to higher distributor commissions on increased sales, higher sales salary resulting from increased headcount and higher advertising and marketing expenses. The Company continues to invest in sales and marketing in order to gain market share. The Company’s strategy to leverage its existing distributor network with product specialists domestically resulted in part in domestic sales growing by 28.9% during the first nine months of fiscal 2017. This expense increase was partially offset by a decrease in depreciation of consigned units of $382,000, resulting from a change in accounting estimate to depreciate these units over five years in fiscal 2017 compared with three years in fiscal 2016.

General and administrative expenses

General and administrative expenses increased by $1,509,633, or 30.2% to $6,504,202 in the first nine months of fiscal 2017 from $4,994,569 in the prior year period. The increase resulted principally from increased professional fees of $2.0 million relating to the Investigation. The Company also accrued for severance for its former CEO during the current year. This increase was partially offset by a reduction in non-cash stock compensation expense of $805,000, which includes a reversal of stock compensation previously recognized with respect to the Company’s prior CEO relating to unvested stock options which were terminated.

Research and development expenses

Research and development expenses increased by $57,972, or 4.3% to $1,398,311 in the first nine months of fiscal 2017 from $1,340,339 in the prior year period. The increase is due generally to higher salary and consulting costs for increased product development activities.

Other income (expense)

Other income decreased $121,891 to $2,830,831 in the first nine months of fiscal 2017 from $2,952,722 in the prior year period. The decrease is related to lower royalty income from MMIT. This royalty agreement expires in August 2017.

Income taxes

For the nine months ended March 31, 2017 and 2016, the Company recorded an income tax benefit from continuing operations of $275,000 and $322,000, respectively. For the nine months ended March 31, 2017 and 2016, the Company recorded a tax benefit with an effective tax rate of 16.0% and 26.6%, respectively. The effective rate of 16.0% and 26.6%, respectively, on continuing operations varied from the U.S. federal statutory rate due to permanent book to tax differences relating principally to stock compensation expense and tax credits.

Liquidity and Capital Resources

Working capital at March 31, 2017 was $18.4 million. For the nine months ended March 31, 2017, cash used in operations was $1,232,749, mainly due to the Company’s net loss of $1,444,372 and an increase in inventory of $449,986, an increase in accounts receivable of $487,729, offset by $1,379,640 of non-cash depreciation expense and non-cash compensation.

Cash used in investing activities was $425,383, primarily consisting of the purchase of property, plant and equipment along with filing for additional patents.

Cash provided by investing activities was $4,303,447 for the first nine months of fiscal 2017. On October 25, 2016, the Company sold 761,469 shares of Common Stock in a private placement to Stavros G. Vizirgianakis, a director of the Company and its current Chief Executive Officer, at a price per share of $5.253, representing total cash proceeds to the Company of approximately $4.0 million.

As of March 31, 2017, the Company had a cash balance of approximately $11.9 million and believes it has sufficient cash to finance operations for at least the next 12 months.

Relating to the internal investigation described herein, the Company has incurred approximately $2.1 million in investigative costs and is expected to incur additional costs until the matter is fully resolved. Further, the Company could be subject to fines or penalties related to potential violations of the FCPA.

The Company has been receiving an annual royalty from MMIT which has averaged $3.7 million per year over the last three fiscal years. This royalty will end in August 2017.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to the Company.

Other

In the opinion of management, inflation has not had a material effect on the operations of the Company.

Recent Accounting Pronouncements

See Note 1 to our consolidated financial statements included herein.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market Risk:

The principal market risks (i.e., the risk of loss arising from adverse changes in market rates and prices) to which the Company is exposed are interest rates on cash and cash equivalents.

Interest Rate Risk:

The Company earns interest on cash balances and pays interest on debt incurred. In light of the Company’s existing cash, results of operations and projected borrowing requirements, the Company does not believe that a 10% change in interest rates would have a significant impact on its consolidated financial position.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

All internal control systems, no matter how well designed and tested, have inherent limitations, including, among other things, the possibility of human error, circumvention or disregard. Therefore, even those systems of internal control that have been determined to be effective can provide only reasonable assurance that the objectives of the control system are met and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

As described in Part II - Item 1 “Legal Proceedings” in this 10-Q, in April 2016, the Company’s management informed the Board of violations of Company policies and procedures and possible violations of laws and regulations, involving Michael A. McManus, the Company’s former President and Chief Executive Officer, and other Company personnel. Subsequently, in mid-May 2016, the Audit Committee of the Board of Directors initiated the investigation of these matters. Special external counsel was retained and conducted the Investigation with the assistance of an advisory firm with forensic accounting expertise. Mr. McManus’ employment with the Company ceased on September 2, 2016.

The Investigation resulted in the Company notifying the SEC and DOJ about possible violations of the FCPA and other internal controls matters. These possible violations of laws included knowledge of certain business practices of the independent Chinese entity that previously distributed the Company’s products in China, which practices raised questions under the FCPA.

The Investigation did not identify any financial loss to the Company and did not identify any material misstatements in the Company’s financial statements. However, as a result of the Company’s Investigation and related activities, it has incurred approximately $2.1 million of professional fees as of March 31, 2017 and has terminated the agreement with its former distributor in China, which was the Company’s largest customer during the prior three fiscal years. In addition, the Company could be subject to disgorgement, fines or penalties related to potential violations of the FCPA as described in Part II - Item 1 “Legal Proceedings” below.

In connection with the Investigation, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of March 31, 2017. Due to the material weaknesses in internal control over financial reporting as described below in “Internal Control over Financial Reporting”, our current CEO and Interim CFO have concluded that our disclosure controls and procedures were not effective, and were not operating at a reasonable assurance level, as of March 31, 2017.

Internal Control over Financial Reporting

The Company’s management is responsible for establishing and maintaining effective internal control over financial reporting and for assessing the effectiveness of internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting refers to a process designed by, or under the supervision of, our CEO and our CFO and effected by our Board, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:

pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and members of our Board; and

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A material weakness (as defined in Rule 12b-2 under the Exchange Act) is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting as of March 31, 2017, based on the criteria established in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon this evaluation, management has determined, because of the findings from the Investigation, and the Company’s inability to rely on certain personnel, processes and internal controls, that material weaknesses existed at March 31, 2017, as described below. In light of such material weaknesses, management has concluded that the Company’s internal control over financial reporting was ineffective as of March 31, 2017.

The Company did not have an effective control environment, risk assessment process, information and communication process and monitoring activities. These matters related to ineffective ethical governance, ineffective governance controls, and ineffectively implemented policies and procedures. The aggregation of issues identified within each of these areas resulted in the conclusion that a material weakness existed with respect to the “tone at the top” and effectiveness of governance within the Company. Specifically:

The Company failed to establish a tone at the top that demonstrated its commitment to integrity and ethical values.

The Company lacked effective controls and procedures to ensure that all members of management and Board members report to the full Board all possible illegal acts and violations of Company policy.

The Company lacked effective procedures and controls to ensure that all reimbursement requests are handled in a manner consistent with the Board’s authorizations and the Company’s policies and procedures.

The Company did not have effective information and communication and monitoring controls, including a robust whistleblower process, relating to the timely identification and communication of issues among financial reporting personnel, management, the Board, and the independent registered public accounting firm to enable appropriate analysis, financial reporting, and disclosure of such transactions.

In addition, the Company did not properly supervise the preparation and review the calculation of its income tax provision and deferred tax asset. While this control deficiency did not result in a material misstatement of the Company’s financial statements, it could have resulted in misstatements of the aforementioned accounts and disclosures that would not be prevented or detected in a timely manner. Accordingly, our management concluded that this control deficiency also constitutes a material weakness.

The identified control deficiencies did not result in any material misstatements in the Company’s financial statements. However, these control deficiencies created a reasonable possibility that a material misstatement to the consolidated financial statements would not be prevented or detected on a timely basis. Accordingly, we concluded that the control deficiencies represented material weaknesses in the Company’s internal control over financial reporting and our internal control over financial reporting was not effective as of March 31, 2017.

Remediation of Material Weaknesses

The Company continues to work to strengthen our internal control over financial reporting. We are committed to ensuring that such controls are designed and operating effectively. Our Board and management take internal control over financial reporting and the integrity of the Company’s financial statements seriously and believe that the remediation steps described below, including with respect to personnel changes, were and are essential steps to establishing and maintaining strong and effective internal control over financial reporting and addressing the tone at the top concerns that contributed to the material weaknesses identified. Most of these remediation steps have taken place as of March 31, 2017. The following actions and plans will be or have been implemented during the fiscal 2017 year:

	·	The Board replaced Mr. McManus effective September 2, 2016 with our then interim and now current CEO, Stavros G. Vizirgianakis. In addition, on September 13, 2016, the Board appointed Joseph P. Dwyer as the Company’s interim CFO, reporting to the Company’s new CEO and the Audit Committee of the Board. On that date, Richard A. Zaremba ceased serving as the Company’s Senior Vice President and CFO and was appointed Senior Vice President, Finance, while remaining as the Company’s Secretary and Treasurer.

	·	In November 2016, the Company hired an Interim Chief Compliance Officer who reports directly and regularly to the CEO and the Chairman of the Audit Committee. The Interim Chief Compliance Officer is implementing an improved documentary framework, focusing initially on FCPA compliance and working with the Company’s sales and marketing personnel.

The Board, as recommended by the Interim Chief Compliance Officer, reconstituted the Company’s internal compliance committee to include the entire senior management team, with the Chief Compliance Officer as Chair and the sales and marketing officers as non-voting members. This action was designed in part to ensure that all members of senior management report all possible illegal acts.

The Company reconstituted the membership of its Board committees. T. Guy Minetti, former Chairman of our Audit Committee, resigned from the Board on December 15, 2016.

The Board reviewed and updated its Committee charters to provide, among other things, a more robust and structured governance process.

The Company updated its Code of Conduct and Ethics and implemented a toll-free whistleblower hotline that is reported directly to the Chairman of the Audit Committee. In addition, the Company has increased communication and will increase training to employees regarding the ethical values of the Company and the requirement to comply with laws, rules, regulations, and Company policies, including the Code of Conduct and Ethics, and the importance of accurate and transparent financial reporting.

Under the supervision of the Board, the Company will emphasize to key leadership the importance of setting appropriate tone at the top and of appropriate behavior with respect to accurate financial reporting, compliance with laws, and adherence to the Company’s internal control over financial reporting framework and accounting policies.

The Company terminated the agreement with its former independent distributor of its products in China.

The Company is amending distribution agreements with its international distributors to add more fulsome provisions regarding compliance with laws, including compliance with the FCPA and other applicable anti-bribery provisions.

The Company is instituting a more robust screening process for its independent distributors with respect to legal compliance, including compliance with the FCPA and other applicable anti-bribery provisions.

The Company is implementing a regularly recurring risk assessment process focused on identifying and analyzing risks of financial misstatement due to error and/or fraud, including management override of controls.

The Company is updating its policies and procedures to ensure the proper processing of transactions with senior executives, and to enhance the review and approval for these types of transactions and ensure their proper disclosure, and will train relevant employees on such updated policies.

We have engaged a third-party expert consulting firm specializing in tax and technical accounting and financial reporting issues to assist our management with the review of our tax provisions and the accounting treatment and the financial reporting and disclosure of complex and non-recurring transactions.

The Company is in the process of testing these control upgrades. The Company expects these control deficiencies will be fully remediated by June 30, 2017.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2017 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As noted above, the Company is in the process of enhancing existing controls and designing and implementing additional controls and procedures in response to the material weaknesses.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

Class Action Securities Litigation

Former Chinese Distributor - FCPA

Former Chinese Distributor – Litigation

Item 1A. Risk Factors.

Risks and uncertainties that, if they were to occur, could materially adversely affect our business or that could cause our actual results to differ materially from the results contemplated by the forward-looking statements contained in this Report and other public statements were set forth in the Item 1A. – “Risk Factors” section of our Form 10-K for the fiscal year ended June 30, 2016. There have been no material changes from the risk factors disclosed in that Form 10-K.

Item 6. Exhibits

Exhibit No.		Description

31.1		Chief Executive Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Chief Financial Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Chief Executive Officer—Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

32.2		Chief Financial Officer—Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Scheme Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MISONIX, INC.

Dated: May 2, 2017	By:	/s/ Stavros G. Vizirgianakis
		Stavros G. Vizirgianakis
		Chief Executive Officer

	By:	/s/ Joseph P. Dwyer
		Joseph P. Dwyer
		Interim Chief Financial Officer

Exhibit No.		Description
31.1		Chief Executive Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Chief Financial Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Chief Executive Officer—Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

32.2		Chief Financial Officer—Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Scheme Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

EX-31.1 2 s105975_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Stavros G. Vizirgianakis, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Misonix, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 2, 2017	/s/ Stavros G. Vizirgianakis
	Stavros G. Vizirgianakis
	Chief Executive Officer

EX-31.2 3 s105975_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Joseph P. Dwyer, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Misonix, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 2, 2017	/s/ Joseph P. Dwyer
	Joseph P. Dwyer
	Interim Chief Financial Officer

EX-32.1 4 s105975_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Misonix, Inc. (the “Company “) on Form 10-Q for the period ended March 31, 2017 as filed with the Securities and Exchange Commission (the “Report”), I, Stavros G. Vizirgianakis, Chief Executive Officer of the Company, certify, that: (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 2, 2017	/s/ Stavros G. Vizirgianakis
	Stavros G. Vizirgianakis
	Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Misonix, Inc. and will be retained by Misonix, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 s105975_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Misonix, Inc. (the “Company “) on Form 10-Q for the period ended March 31, 2017 as filed with the Securities and Exchange Commission (the “Report”), I, Joseph P. Dwyer, Interim Chief Financial Officer of the Company, certify, that: (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 2, 2017	/s/ Joseph P. Dwyer
	Joseph P. Dwyer
	Interim Chief Financial Officer

GRAPHIC 6 logo_10q.jpg GRAPHIC begin 644 logo_10q.jpg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mson-20170331.xml XBRL INSTANCE FILE 0000880432 2016-07-01 2017-03-31 0000880432 2017-03-31 0000880432 mson:SonaCareMedicalMember 2010-05-09 2010-05-10 0000880432 mson:SonaCareMedicalMember us-gaap:MinimumMember 2010-05-09 2010-05-10 0000880432 mson:SonaCareMedicalMember 2016-07-01 2017-03-31 0000880432 mson:CicelScienceAndTechCoLtdMember 2016-07-01 2017-03-31 0000880432 mson:CicelScienceAndTechCoLtdMember 2015-07-01 2016-03-31 0000880432 mson:CicelScienceAndTechCoLtdMember 2017-03-31 0000880432 mson:CicelScienceAndTechCoLtdMember 2016-06-30 0000880432 mson:MedtronicMinimallyInvasiveTherapiesMember 2017-03-31 0000880432 mson:MedtronicMinimallyInvasiveTherapiesMember 2016-06-30 0000880432 us-gaap:GeographicDistributionForeignMember 2017-03-31 0000880432 us-gaap:GeographicDistributionForeignMember 2016-06-30 0000880432 mson:LicenseAgreementMember mson:MedtronicMinimallyInvasiveTherapiesMember 2016-07-01 2017-03-31 0000880432 mson:LicenseAgreementMember mson:MedtronicMinimallyInvasiveTherapiesMember 2015-07-01 2016-03-31 0000880432 2016-06-30 0000880432 2015-07-01 2016-03-31 0000880432 mson:InventoryMember 2016-07-01 2017-03-31 0000880432 mson:GeneratorsMember 2016-07-01 2017-03-31 0000880432 mson:GeneratorsMember 2015-07-01 2016-03-31 0000880432 us-gaap:PatentsMember 2017-03-31 0000880432 us-gaap:PatentsMember 2016-06-30 0000880432 us-gaap:PatentsMember 2016-07-01 2017-03-31 0000880432 us-gaap:PatentsMember 2015-07-01 2016-03-31 0000880432 us-gaap:EmployeeStockOptionMember 2016-07-01 2017-03-31 0000880432 us-gaap:SubsequentEventMember 2016-07-01 2017-06-30 0000880432 us-gaap:RestrictedStockMember us-gaap:ChiefExecutiveOfficerMember 2016-12-14 2016-12-15 0000880432 us-gaap:BuildingMember 2016-07-01 2017-03-31 0000880432 mson:OfficeEquipmentAndAutomobilesMember 2016-07-01 2017-03-31 0000880432 us-gaap:PresidentMember mson:AppliedBioSurgicalMember 2016-07-01 2017-03-31 0000880432 us-gaap:PresidentMember mson:AppliedBioSurgicalMember 2015-07-01 2016-03-31 0000880432 us-gaap:PresidentMember mson:AppliedBioSurgicalMember 2017-03-31 0000880432 us-gaap:PresidentMember us-gaap:PrivatePlacementMember 2016-10-24 2016-10-25 0000880432 us-gaap:PrivatePlacementMember us-gaap:PresidentMember 2016-10-25 0000880432 mson:LicenseAgreementMember mson:MedtronicMinimallyInvasiveTherapiesMember 1996-10-01 1996-10-31 0000880432 us-gaap:GeographicDistributionDomesticMember 2016-07-01 2017-03-31 0000880432 us-gaap:GeographicDistributionDomesticMember 2015-07-01 2016-03-31 0000880432 us-gaap:GeographicDistributionForeignMember 2016-07-01 2017-03-31 0000880432 us-gaap:GeographicDistributionForeignMember 2015-07-01 2016-03-31 0000880432 mson:FormerPresidentMember mson:RetirementAgreementAndGeneralReleaseMember 2016-08-25 2016-08-26 0000880432 mson:FormerPresidentMember mson:RetirementAgreementAndGeneralReleaseMember 2016-07-01 2017-03-31 0000880432 us-gaap:CommonStockMember 2016-07-01 2017-03-31 0000880432 us-gaap:CommonStockMember 2016-06-30 0000880432 us-gaap:CommonStockMember 2017-03-31 0000880432 us-gaap:TreasuryStockMember 2016-06-30 0000880432 us-gaap:TreasuryStockMember 2017-03-31 0000880432 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2017-03-31 0000880432 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0000880432 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0000880432 us-gaap:RetainedEarningsMember 2016-07-01 2017-03-31 0000880432 us-gaap:RetainedEarningsMember 2016-06-30 0000880432 us-gaap:RetainedEarningsMember 2017-03-31 0000880432 2016-03-31 0000880432 2015-06-30 0000880432 2017-01-01 2017-03-31 0000880432 2016-01-01 2016-03-31 0000880432 us-gaap:PresidentMember mson:AppliedBioSurgicalMember 2016-03-31 0000880432 mson:FormerPresidentMember mson:RetirementAgreementAndGeneralReleaseMember 2016-07-01 2016-09-30 0000880432 2017-04-28 0000880432 us-gaap:PatentsMember 2017-01-01 2017-03-31 0000880432 us-gaap:PatentsMember 2016-01-01 2016-03-31 0000880432 us-gaap:RestrictedStockMember us-gaap:ChiefExecutiveOfficerMember 2017-01-01 2017-03-31 0000880432 us-gaap:RestrictedStockMember us-gaap:ChiefExecutiveOfficerMember 2016-07-01 2017-03-31 0000880432 mson:LicenseAgreementMember mson:MedtronicMinimallyInvasiveTherapiesMember 2017-01-01 2017-03-31 0000880432 mson:LicenseAgreementMember mson:MedtronicMinimallyInvasiveTherapiesMember 2016-01-01 2016-03-31 0000880432 mson:SonaCareMedicalMember 2017-01-01 2017-03-31 0000880432 mson:SonaCareMedicalMember 2016-01-01 2016-03-31 0000880432 us-gaap:GeneralAndAdministrativeExpenseMember mson:FormerChineseDistributorMember 2016-07-01 2017-03-31 0000880432 mson:FormerChineseDistributorMember 2016-07-01 2017-03-31 0000880432 mson:FormerChineseDistributorMember 2017-01-01 2017-03-31 0000880432 mson:CicelScienceAndTechCoLtdMember 2017-01-01 2017-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure mson:N MISONIX INC 0000880432 10-Q MSON 2017-03-31 false --06-30 No No Yes Accelerated Filer Q3 2017 9023354 11856503 9049327 8357090 9623749 21787323 19272253 4909415 5822935 4357156 3869427 664249 530564 3413116 2492815 710070 604916 710070 604916 1701094 1701094 300341 266603 3581551 3394690 31493495 27732371 1433608 1402797 1994387 1887337 3427995 3290134 9331 9262 17737 31685 3455063 3331081 91622 79482 -8363872 -7081361 37410034 32502521 1099352 1099352 28038432 24401290 79482 91622 -1099352 -1099352 32502521 37410034 -7081361 -8363872 31493495 27732371 96868 96868 7610152 6976282 965996 885394 0.01 0.01 20000000 20000000 9162203 7948234 9023354 7809385 138849 138849 19379768 0 1337277 16716487 12019103 9324928 7360665 7391559 7177763 5426147 8000000 5842778 5578349 2112099 1859749 13536990 11138138 5065664 3566398 10184680 8967352 3587859 3319385 6504202 4994569 2484962 1515559 1398311 1340339 465863 548278 18087193 15302260 6538684 5383222 -4550203 -4164122 -1473020 -1816824 56 63 18 19 2846351 2969557 953235 963025 -15576 -16898 -6940 -5464 2830831 2952722 946313 957580 -1719372 -1211400 -526707 -859244 -1444372 -889400 -307707 -844244 161861 165000 161861 165000 161861 165000 161861 165000 -1282511 -724400 -1282511 -145846 -679244 -0.17 -0.11 -0.04 -0.11 -0.17 -0.11 -0.04 -0.11 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 -0.16 -0.09 -0.02 -0.09 -0.16 -0.09 -0.02 -0.09 8263343 7772761 8613354 7789174 8263343 7772761 8613354 7789174 88139 85000 88139 85000 7948234 9162203 -138849 -138849 4000000 7615 3992385 400000 761469 4000 -4000 400000 303447 525 302922 -52500 52500 616206 616206 763434 1271864 -186861 -260000 -69 -6947 13948 20852 616206 1175165 532341 446172 224498 265063 -1232749 -1100804 137861 141624 167423 282221 449986 2623620 487729 -379689 -425383 -482102 185756 71541 239627 410561 4303447 151247 303447 151247 4000000 161861 165000 161861 165000 2807176 -1266659 1363506 1017506 9866 141120 1.00 5800000 1504788 0.07 3000000 0.05 5800000 250000 2838487 2932240 953235 956947 250000 250000 369463 0 953000 973000 762000 768000 2481557 3102175 708593 854631 3004743 3101234 6194893 7058040 1285478 1235105 682832 982984 533000 253515 345355 3 to 5 years P5Y P3Y 28239 110790 102484 79055 72884 316618 P17Y 80602 69897 27877 23090 676882 648705 300000 300000 429000 433000 228584 256130 29491 20655 99859 230571 228847 1994387 1887337 0.0180 0.0171 P6Y3M P6Y3M 0.5468 0.5541 0.00 0.00 1685899 1790224 327500 376625 2700 980774 6.37 6.38 8.34 5.78 8.24 3.45 4.63 9324182 1675072 7097409 2771938 P2Y9M18D P10Y P4Y P5Y 4.46 4.23 1055434 3400000 224250 976875 4.71 4.81 616239 81765 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">Expiring through fiscal 2018.</td></tr> </table> 26000 Monthly 250000 2000000 2100000 650000 367592 349490 104678 212981 761469 5.253 4000000 0.160 0.266 2017-08 0.05 1 the Company agreed to (i) pay Mr. McManus’ salary through June 30, 2017 at the then current level; (ii) continue to pay premiums for Mr. McManus’ and his dependents’ coverage under the Company’s medical, dental, vision, hospitalization, long term care and life insurance coverage through June 30, 2017 at the then current levels upon timely election by Mr. McManus under the law informally known as COBRA; and (iii) extend the exercisability of previously granted and then currently vested options to purchase shares of Common Stock through June 30, 2017. 61000 596000 330000 0.080 0.10 -275000 -322000 -219000 -15000 512750 486000 145750 844250 1. Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies   Basis of Presentation   These consolidated financial statements of Misonix, Inc. (“Misonix” or the “Company”) include the accounts of Misonix and its 100% owned subsidiaries. All significant intercompany balances and transactions have been eliminated.   The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. As such, they should be read with reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which provides a more complete explanation of the Company’s accounting policies, financial position, operating results, business properties and other matters. In the opinion of management, these financial statements reflect all adjustments considered necessary for a fair statement of interim results.   Reclassifications   Certain expenses on the Statement of Operations have been reclassified to be consistent with the current year presentation. Historically, the Company had recorded stock compensation expense and bonus expense predominantly within general and administrative expenses. The Company has reclassified the prior years’ presentation to allocate certain of these costs to cost of goods sold, selling expenses and research and development expenses, which is consistent with the classification being used in fiscal 2017. This reclassification had no impact on the Company’s presentation of operating income (loss) and the gross profit impact was not material.   Organization and Business   Misonix designs, manufactures, develops and markets therapeutic ultrasonic devices. These products are used for precise bone sculpting, removal of soft tumors, and tissue debridement in the fields of orthopedic surgery, plastic surgery, neurosurgery, podiatry and vascular surgery. In the United States, the Company sells its products through a network of commissioned agents assisted by Company personnel. Outside of the United States, the Company sells to distributors who then resell the product to hospitals. The Company operates as one business segment.   High Intensity Focused Ultrasound Technology   The Company sold its rights to the high intensity focused ultrasound technology to SonaCare Medical, LLC (“SonaCare”) in May 2010. The Company may receive up to approximately $5.8 million in payment for the sale. SonaCare will pay the Company 7% of the gross revenues received from its sales of the (i) prostate product in Europe and (ii) kidney and liver products worldwide, until the Company has received payments of $3 million, and thereafter 5% of the gross revenues, up to an aggregate payment of $5.8 million, all subject to a minimum annual royalty of $250,000. Cumulative payments through March 31, 2017 were $1,504,788. Payments are generally received once per year, in the Company’s third fiscal quarter. For the three months ended March 31, 2017 and 2016, the Company received a royalty of $250,000 in each quarter, which has been recorded in discontinued operations.   Major Customers and Concentration of Credit Risk   Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. (“Cicel”) of $0 and $1,337,277 for the nine months ended March 31, 2017 and 2016, respectively, representing 8.0% of sales for 2016. There were no accounts receivable from Cicel at March 31, 2017 and June 30, 2016. The Company terminated its agreement with Cicel in the first quarter of fiscal 2017.   For the three months ended March 31, 2017, one international distributor accounted for approximately 10% of sales for the quarter. In addition, this same customer had outstanding accounts receivable at March 31, 2017 of $369,463.   Total royalties from Medtronic Minimally Invasive Therapies (“MMIT”) related to their sales of the Company’s ultrasonic cutting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $2,838,487 and $2,930,240, for the nine months ended March 31, 2017 and 2016, respectively. Accounts receivable from MMIT royalties were approximately $953,000 and $973,000 at March 31, 2017 and June 30, 2016, respectively. The license agreement with MMIT expires in August 2017.   At March 31, 2017 and June 30, 2016, the Company’s accounts receivable with customers outside the United States were approximately $762,000 and $768,000, respectively, none of which is over 90 days.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for, but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and related valuation allowances, and stock-based compensation. Actual results could differ from those estimates.   Loss per Common Share   Diluted EPS for the three and nine months ended March 31, 2017 and March 31, 2016 as presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. Accordingly, excluded from the calculation of diluted EPS are outstanding options to purchase 145,750 and 512,750 shares of common stock for the three and nine months ended March 31, 2017, and options to purchase 844,250 and 486,000 shares of common stock for the three and nine months ended March 31, 2016.     Recent Accounting Pronouncements   In January 2017, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will apply this guidance to applicable impairment tests after January 1, 2017.   In February 2016, the FASB issued guidance on lease accounting requiring lessees to recognize a right-of-use asset and a lease liability for long-term leases. The liability will be equal to the present value of lease payments. This guidance must be applied using a modified retrospective transition approach to all annual and interim periods presented and is effective for the Company beginning in fiscal 2019. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.   In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes (Topic740)”. The amendments in this ASU require deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments eliminate the guidance in Topic 740 that requires an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount in a classified statement of financial position. The Company adopted ASU 2015-17 as of March 31, 2016 on a prospective basis in order to simplify the balance sheet classification of deferred taxes.    In May 2014, the FASB issued guidance on revenue from contracts with customers. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved, in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. This guidance permits the use of either the retrospective or cumulative effect transition method and is effective for the Company beginning in 2019; early adoption is permitted beginning in 2018. The Company has not yet selected a transition method and is currently evaluating the impact of the guidance on the Company's financial condition, results of operations and related disclosures. The FASB has also issued the following additional guidance clarifying certain issues on revenue from contracts with customers: Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients and Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.    There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows. 2. Fair Value of Financial Instruments   We follow a three-level fair value hierarchy that prioritizes the inputs to measure fair value. This hierarchy requires entities to maximize the use of "observable inputs" and minimize the use of "unobservable inputs." The three levels of inputs used to measure fair value are as follows:   Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets as of the measurement date.   Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.   Level 3: Significant unobservable inputs that reflect assumptions that market participants would use in pricing an asset or liability.   At March 31, 2017 and June 30, 2016, all of our cash, trade accounts receivable and trade accounts payable were short term in nature, and their carrying amounts approximate fair value. 3. Inventories   Inventories are summarized as follows:   <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">March 31,</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">June 30,</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Raw material</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">2,481,557</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">3,102,175</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Work-in-process</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">708,593</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">854,631</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Finished goods</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,004,743</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,101,234</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,194,893</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,058,040</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Less valuation reserve</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,285,478</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,235,105</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4,909,415</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">5,822,935</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4. Property, Plant and Equipment   Depreciation and amortization of property, plant and equipment was $253,515 and $345,355 for the three months ended March 31, 2017 and 2016, respectively, and was $682,832 and $982,984 for the nine months ended March 31, 2017 and 2016, respectively. Inventory items included in property, plant and equipment are depreciated using the straight line method over estimated useful lives of 3 to 5 years. Depreciation of generators which are consigned to customers is expensed over a 5 year period during the nine months ended March 31, 2017 and is expensed over a 3 year period for the nine months ended March 31, 2016, and depreciation is charged to selling expenses. The impact of this change in accounting estimate was a reduction in expense of approximately $533,000 for the nine months ended March 31, 2017, compared to what the expense would have been without this change. 5. Goodwill   Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or products. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long term rate of growth for the Company’s business, the useful lives over which cash flows will occur and determination of the Company’s weighted average cost of capital. The Company primarily utilizes the Company’s market capitalization and a discontinued cash flow model in determining the fair value which consists of Level 3 inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. The Company completed its annual goodwill impairment tests for fiscal 2016 and 2015 as of June 30 of each year. No impairment of goodwill was deemed to exist in fiscal 2016 and 2015. 6. Patents   The costs of acquiring or processing patents are capitalized at cost. These amounts are being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Patents totaled $710,070 and $604,916 at March 31, 2017 and June 30, 2016, respectively. Amortization expense for the three months ended March 31, 2017 and 2016 was $27,877and $23,090, respectively, and for the nine months ended March 31, 2017 and 2016 was $80,602 and $69,897, respectively.   The following is a schedule of estimated future patent amortization expense as of March 31, 2017:   <table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: left">2017</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">28,239</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2018</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">110,790</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2019</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">102,484</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">79,055</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72,884</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">316,618</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">710,070</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 7. Accrued Expenses and Other Current Liabilities   The following summarizes accrued expenses and other current liabilities:    <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">March 31,</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">June 30,</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accrued payroll, payroll taxes and vacation</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">676,882</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">648,705</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Accrued bonus</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued commissions</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">429,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">433,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">228,584</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">256,130</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred income</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">29,491</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,655</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Severance</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">99,859</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">230,571</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">228,847</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,994,387</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,887,337</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 8. Stock-Based Compensation Plans   Stock Option Awards    For the three and nine months ended March 31, 2017, the compensation cost that has been charged against income for the Company’s stock option plans was $532,341 and $616,206, respectively, which in the nine month period included a charge to modify certain stock options of $81,765 and a reversal of stock compensation from prior periods due to forfeitures of unvested options of $616,239. For the three and nine months ended March 31, 2016, compensation cost that has been charged against income for the Company’s stock option plans was $446,172 and $1,175,000, respectively. As of March 31, 2017, there was approximately $2,771,938 of total unrecognized compensation cost related to non-vested share-based compensation arrangements to be recognized over a weighted-average period of 2.8 years.     Stock options typically expire 10 years from the date of grant and vest over service periods, which typically are 4 years. All options are granted at fair market value, as defined in the applicable plans.   The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. The expected volatility represents the historical price changes of the Company’s stock over a period equal to that of the expected term of the option. The Company uses the simplified method for determining the option term. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The expected dividend yield is based upon historical and projected dividends. The Company has historically not paid dividends, and is not expected to do so in the near term.   The weighted average fair value at date of grant for options granted during the nine months ended March 31, 2017 and 2016 was $4.46 and $4.23, respectively. There were options to purchase 327,500 shares granted during the nine months ended March 31, 2017. The fair value was estimated based on the weighted average assumptions of:   <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">For nine months ended March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Risk-free interest rates</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">1.80</td> <td style="width: 1%; text-align: left">%</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">1.71</td> <td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Expected option life in years</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.25</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.25</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">54.68</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">55.41</td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Expected dividend yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0</td> <td style="text-align: left">%</td></tr> </table>   A summary of option activity under the Company’s equity plans as of March 31, 2017, and changes during the nine months ended March 31, 2017 is presented below:   <table cellspacing="0" cellpadding="0" align="center" style="width: 85%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Outstanding  Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Average Exercise  Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Aggregate Instrinsic Value</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Vested and exercisable at June 30, 2016</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">1,790,224</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">6.38</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">1,675,072</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">327,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">8.34</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(52,500</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.78</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(376,625</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">8.24</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,700</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">3.45</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,685,899</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">6.37</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">9,324,182</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Vested and exercisable at March 31, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">980,774</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4.63</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,097,409</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The total fair value of shares vested during the nine months ended March 31, 2017 was $1,055,434. The number and weighted-average grant-date fair value of non-vested stock options at the beginning of fiscal 2017 was 976,875 and $4.81, respectively. The number and weighted-average grant-date fair value of stock options which vested during the nine months ended March 31, 2017 was 224,250 and $4.71, respectively.   Restricted Stock Awards   On December 15, 2016, the Company issued 400,000 shares of restricted stock to its Chief Executive Officer. These awards vest over a period of up to five years, subject to meeting certain service, performance and market conditions. These awards were valued at approximately $3.4 million and compensation expense recorded in the three and nine months ended March 31, 2017 was $224,498 and $265,063, respectively. 9. Commitments and Contingencies   Leases   The Company has entered into several non-cancellable operating leases for the rental of certain manufacturing and office space, equipment and automobiles expiring in various years through 2021. The principal building lease provides for a monthly rental of approximately $26,000. The Company also leases certain office equipment and automobiles under operating leases expiring through fiscal 2018.   Class Action Securities Litigation   On September 19, 2016, Richard Scalfani, an individual shareholder of Misonix, filed a lawsuit against the Company and its former CEO and CFO in the U.S. District Court for the Eastern District of New York, alleging violations of the federal securities laws. The complaint alleges that the Company’s stock price was artificially inflated between November 5, 2015 and September 14, 2016 as a result of alleged false and misleading statements in the Company’s securities filings concerning the Company’s business, operations, and prospects and the Company’s internal control over financial reporting. Scalfani filed the action seeking to represent a putative class of all persons (other than defendants, officers and directors of the Company, and their affiliates) who purchased publicly traded Misonix securities between November 5, 2015 and September 14, 2016. Scalfani seeks an unspecified amount of damages for himself and for the putative class under the federal securities laws. On March 24, 2017, the Court appointed Scalfani and another individual Misonix shareholder, Tracey Angiuoli, as lead plaintiffs for purposes of pursuing the action on behalf of the putative class. The Company believes it has various legal and factual defenses to the allegations in the complaint, and intends to vigorously defend the action. The case is at its earliest stages; there has been no discovery and there is no trial date. The Company is not able to estimate the amount of potential loss it may recognize, if any, from this claim. The Company believes that its insurance coverage is sufficient to cover a potential loss, after payment of the policy retention of $250,000.   Former Chinese Distributor - FCPA   For several months, with the assistance of outside counsel, the Company conducted a voluntary investigation into the business practices of the independent Chinese entity that previously distributed its products in China and the Company’s knowledge of those business practices, which may have implications under the FCPA, as well as into various internal controls issues identified during the investigation.   On September 27, 2016 and September 28, 2016, we voluntarily contacted the SEC and the DOJ, respectively, to advise both agencies of these potential issues.  The Company has provided and will continue to provide documents and other information to the SEC and the DOJ, and is cooperating fully with these agencies in their investigations of these matters.   Although the Company’s investigation is complete, additional issues or facts could arise which may expand the scope or severity of the potential violations.  The Company has no current information derived from the investigation or otherwise to suggest that its previously reported financial statements and results are incorrect.   At this stage, the Company is unable to predict what, if any, action the DOJ or the SEC may take or what, if any, penalties or remedial measures these agencies may seek.  Nor can the Company predict the impact on the Company as a result of these matters, which may include the imposition of fines, civil and criminal penalties, which are not currently estimable, as well as equitable remedies, including disgorgement of any profits earned from improper conduct and injunctive relief, limitations on the Company’s conduct, and the imposition of a compliance monitor.  The DOJ and the SEC periodically have based the amount of a penalty or disgorgement in connection with an FCPA action, at least in part, on the amount of profits that a company obtained from the business in which the violations of the FCPA occurred.  During its distributorship relationship with the prior Chinese distributor from 2010 through 2016, the Company generated sales of approximately $8 million from the relationship.    Further, the Company may suffer other civil penalties or adverse impacts, including lawsuits by private litigants in addition to the lawsuit that has already been filed, or investigations and fines imposed by local authorities. The investigative costs to date are approximately $2.1 million, of which approximately $2.0 million was charged to general and administrative expenses during the nine months ended March 31, 2017. Investigative costs for the three months ended March 31, 2017 were approximately $650,000.    Former Chinese Distributor – Litigation   On April 5, 2017, the Company’s former distributor in China, Cicel (Beijing) Science & Technology Co., Ltd., filed a lawsuit against the Company and certain officers and directors of the Company in the United States District Court for the Eastern District of New York, alleging that the Company improperly terminated its contract with the former distributor. The complaint, which seeks various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, asserts various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. The Company believes it has various legal and factual defenses to the allegations in the complaint, and intends to vigorously defend the action. The case is at its earliest stages; there has been no discovery and there is no trial date. 10. Related Party Transactions   Applied BioSurgical, a company owned by the brother of the Company’s Chief Executive Officer, Stavros G. Vizirgianakis, is an independent distributor for the Company outside of the United States.   Set forth below is a table showing the Company’s net sales for the nine months ended March 31 and accounts receivable at March 31 for the indicated time periods below with Applied BioSurgical:   <table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Sales</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">367,592</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">349,490</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Accounts receivable</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">104,678</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">212,981</td> <td style="text-align: left"> </td></tr> </table>   On October 25, 2016, the Company sold 761,469 shares of Common Stock in a private placement to Stavros G. Vizirgianakis, the Company’s current Chief Executive Officer, at a price per share of $5.253, representing total cash proceeds to the Company of approximately $4.0 million. 11. Income Taxes   For the three months ended March 31, 2017 and 2016, the Company recorded an income tax benefit from continuing operations of $219,000 and $15,000, respectively, and for the nine months ended March 31, 2017 and 2016, the Company recorded an income tax benefit from continuing operations of $275,000 and $322,000, respectively.   For the nine months ended March 31, 2017 and 2016, the effective rate of 16.0% and 26.6%, respectively, on continuing operations varied from the U.S. federal statutory rate primarily due to permanent book tax differences relating principally to stock compensation expense and tax credits.   As of March 31, 2017 and June 30, 2016, the Company has no material unrecognized tax benefits or accrued interest and penalties. 12. Licensing Agreements for Medical Technology   In October 1996, the Company entered into a License Agreement with MMIT expiring August 2017, covering the further development and commercial exploitation of the Company's medical technology relating to laparoscopic products, which uses high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery. The MMIT license provides for exclusive worldwide marketing and sales rights for this technology. The Company receives a 5% royalty on sales of these products by MMIT. Royalties from this license agreement were $953,235 and $956,947 for the three months ended March 31, 2017 and 2016, respectively, and were $2,838,487 and $2,932,240 for the nine months ended March 31, 2017 and 2016, respectively. 13. Segment Reporting   Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker (“CODM") in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company has concluded that its Chief Executive Officer is the CODM as he is the ultimate decision maker for key operating decisions, determining the allocation of resources and assessing the financial performance of the Company. These decisions, allocations and assessments are performed by the CODM using consolidated financial information. Consolidated financial information is utilized by the CODM as the Company's current product offering primarily consists of minimally invasive therapeutic ultrasonic medical devices. The Company's products are relatively consistent and manufacturing is centralized and consistent across product offerings. Based on these factors, key operating decisions and resource allocations are made by the CODM using consolidated financial data and as such the Company has concluded that it operates as one segment.    Worldwide revenue for the Company's products is categorized as follows:   <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td colspan="6" nowrap="nowrap" style="text-align: center">For the Nine Months Ended</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">March 31</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Domestic</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">12,019,103</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">9,324,928</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">International</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,360,665</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,391,559</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">19,379,768</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">16,716,487</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   Substantially all of the Company’s long-lived assets are located in the United States. 14. Severance   On August 26, 2016, the Company and the Company’s former Chief Executive Officer, Michael McManus (“McManus”) entered into a retirement agreement and general release (the “Retirement Agreement”). Pursuant to the Retirement Agreement, on September 2, 2016 Mr. McManus resigned as a Director and the Chairman of the Board of Directors of the Company and retired as President and Chief Executive Officer of the Company. Pursuant to the Retirement Agreement, the Company agreed to (i) pay Mr. McManus’ salary through June 30, 2017 at the then current level; (ii) continue to pay premiums for Mr. McManus’ and his dependents’ coverage under the Company’s medical, dental, vision, hospitalization, long term care and life insurance coverage through June 30, 2017 at the then current levels upon timely election by Mr. McManus under the law informally known as COBRA; and (iii) extend the exercisability of previously granted and then currently vested options to purchase shares of Common Stock through June 30, 2017. In addition, Mr. McManus had continued use of the vehicle provided him pursuant to his prior employment agreement through December 31, 2016. In connection with this Retirement Agreement, the Company recorded a charge of $330,000 during the quarter ended September 30, 2016 to accrue for the cash portion of these benefits, which will be paid during the period ending June 30, 2017. In addition, the Company recorded a non-cash compensation expense of $61,000 in connection with the modification of the terms of his vested stock options, and recorded a reduction in non-cash compensation expense of $596,000 relating to the forfeiture of his unvested stock options. Basis of Presentation   These consolidated financial statements of Misonix, Inc. (“Misonix” or the “Company”) include the accounts of Misonix and its 100% owned subsidiaries. All significant intercompany balances and transactions have been eliminated.   The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. As such, they should be read with reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which provides a more complete explanation of the Company’s accounting policies, financial position, operating results, business properties and other matters. In the opinion of management, these financial statements reflect all adjustments considered necessary for a fair statement of interim results. Reclassifications   Certain expenses on the Statement of Operations have been reclassified to be consistent with the current year presentation. Historically, the Company had recorded stock compensation expense and bonus expense predominantly within general and administrative expenses. The Company has reclassified the prior years’ presentation to allocate certain of these costs to cost of goods sold, selling expenses and research and development expenses, which is consistent with the classification being used in fiscal 2017. This reclassification had no impact on the Company’s presentation of operating income (loss) and the gross profit impact was not material. Organization and Business   Misonix designs, manufactures, develops and markets therapeutic ultrasonic devices. These products are used for precise bone sculpting, removal of soft tumors, and tissue debridement in the fields of orthopedic surgery, plastic surgery, neurosurgery, podiatry and vascular surgery. In the United States, the Company sells its products through a network of commissioned agents assisted by Company personnel. Outside of the United States, the Company sells to distributors who then resell the product to hospitals. The Company operates as one business segment. High Intensity Focused Ultrasound Technology   The Company sold its rights to the high intensity focused ultrasound technology to SonaCare Medical, LLC (“SonaCare”) in May 2010. The Company may receive up to approximately $5.8 million in payment for the sale. SonaCare will pay the Company 7% of the gross revenues received from its sales of the (i) prostate product in Europe and (ii) kidney and liver products worldwide, until the Company has received payments of $3 million, and thereafter 5% of the gross revenues, up to an aggregate payment of $5.8 million, all subject to a minimum annual royalty of $250,000. Cumulative payments through March 31, 2017 were $1,504,788. Payments are generally received once per year, in the Company’s third fiscal quarter. For the three months ended March 31, 2017 and 2016, the Company received a royalty of $250,000 in each quarter, which has been recorded in discontinued operations. Major Customers and Concentration of Credit Risk   Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. (“Cicel”) of $0 and $1,337,277 for the nine months ended March 31, 2017 and 2016, respectively, representing 8.0% of sales for 2016. There were no accounts receivable from Cicel at March 31, 2017 and June 30, 2016. The Company terminated its agreement with Cicel in the first quarter of fiscal 2017.   For the three months ended March 31, 2017, one international distributor accounted for approximately 10% of sales for the quarter. In addition, this same customer had outstanding accounts receivable at March 31, 2017 of $369,463.   Total royalties from Medtronic Minimally Invasive Therapies (“MMIT”) related to their sales of the Company’s ultrasonic cutting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $2,838,487 and $2,930,240, for the nine months ended March 31, 2017 and 2016, respectively. Accounts receivable from MMIT royalties were approximately $953,000 and $973,000 at March 31, 2017 and June 30, 2016, respectively. The license agreement with MMIT expires in August 2017.   At March 31, 2017 and June 30, 2016, the Company’s accounts receivable with customers outside the United States were approximately $762,000 and $768,000, respectively, none of which is over 90 days. Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for, but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and related valuation allowances, and stock-based compensation. Actual results could differ from those estimates. Loss per Common Share   Diluted EPS for the three and nine months ended March 31, 2017 and March 31, 2016 as presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. Accordingly, excluded from the calculation of diluted EPS are outstanding options to purchase 145,750 and 512,750 shares of common stock for the three and nine months ended March 31, 2017, and options to purchase 844,250 and 486,000 shares of common stock for the three and nine months ended March 31, 2016. Recent Accounting Pronouncements   In January 2017, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will apply this guidance to applicable impairment tests after January 1, 2017.   In February 2016, the FASB issued guidance on lease accounting requiring lessees to recognize a right-of-use asset and a lease liability for long-term leases. The liability will be equal to the present value of lease payments. This guidance must be applied using a modified retrospective transition approach to all annual and interim periods presented and is effective for the Company beginning in fiscal 2019. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.   In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes (Topic740)”. The amendments in this ASU require deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments eliminate the guidance in Topic 740 that requires an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount in a classified statement of financial position. The Company adopted ASU 2015-17 as of March 31, 2016 on a prospective basis in order to simplify the balance sheet classification of deferred taxes.    In May 2014, the FASB issued guidance on revenue from contracts with customers. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved, in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. This guidance permits the use of either the retrospective or cumulative effect transition method and is effective for the Company beginning in 2019; early adoption is permitted beginning in 2018. The Company has not yet selected a transition method and is currently evaluating the impact of the guidance on the Company's financial condition, results of operations and related disclosures. The FASB has also issued the following additional guidance clarifying certain issues on revenue from contracts with customers: Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients and Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.    There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows. Inventories are summarized as follows:   <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">March 31,</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">June 30,</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Raw material</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">2,481,557</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">3,102,175</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Work-in-process</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">708,593</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">854,631</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Finished goods</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,004,743</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,101,234</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,194,893</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,058,040</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Less valuation reserve</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,285,478</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,235,105</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4,909,415</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">5,822,935</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following is a schedule of estimated future patent amortization expense as of March 31, 2017:   <table cellspacing="0" cellpadding="0" align="center" style="width: 45%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: left">2017</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">28,239</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2018</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">110,790</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2019</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">102,484</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">79,055</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72,884</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">316,618</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">710,070</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> The following summarizes accrued expenses and other current liabilities:    <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">March 31,</td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center">June 30,</td> <td nowrap="nowrap" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accrued payroll, payroll taxes and vacation</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">676,882</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">648,705</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Accrued bonus</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">300,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued commissions</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">429,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">433,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Professional fees</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">228,584</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">256,130</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred income</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">29,491</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,655</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Severance</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">99,859</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">230,571</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">228,847</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,994,387</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,887,337</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The fair value was estimated based on the weighted average assumptions of:   <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">For nine months ended March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Risk-free interest rates</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">1.80</td> <td style="width: 1%; text-align: left">%</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">1.71</td> <td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Expected option life in years</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.25</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.25</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">54.68</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">55.41</td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Expected dividend yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0</td> <td style="text-align: left">%</td></tr> </table> A summary of option activity under the Company’s equity plans as of March 31, 2017, and changes during the nine months ended March 31, 2017 is presented below:   <table cellspacing="0" cellpadding="0" align="center" style="width: 85%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Outstanding  Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Average Exercise  Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Aggregate Instrinsic Value</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Vested and exercisable at June 30, 2016</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 15%; text-align: right">1,790,224</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">6.38</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">1,675,072</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">327,500</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">8.34</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(52,500</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">5.78</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(376,625</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">8.24</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,700</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">3.45</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">1,685,899</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">6.37</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">9,324,182</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Vested and exercisable at March 31, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">980,774</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">4.63</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">7,097,409</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Set forth below is a table showing the Company’s net sales for the nine months ended March 31 and accounts receivable at March 31 for the indicated time periods below with Applied BioSurgical:   <table cellspacing="0" cellpadding="0" align="center" style="width: 50%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Sales</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">367,592</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">349,490</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Accounts receivable</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">104,678</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">212,981</td> <td style="text-align: left"> </td></tr> </table> Worldwide revenue for the Company's products is categorized as follows:   <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap"> </td> <td colspan="6" nowrap="nowrap" style="text-align: center">For the Nine Months Ended</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">March 31</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Domestic</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">12,019,103</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">9,324,928</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">International</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,360,665</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,391,559</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">19,379,768</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">16,716,487</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> EX-101.SCH 8 mson-20170331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statement of Shareholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000008 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Patents link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stock-Based Compensation Plans link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Licensing Agreements for Medical Technology link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Severance link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Patents (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stock-Based Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Property, Plant and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Patents (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Patents (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stock-Based Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stock-Based Compensation Plans (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Stock-Based Compensation Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Licensing Agreements for Medical Technology (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Segment Reporting (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Severance (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 mson-20170331_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 mson-20170331_def.xml XBRL DEFINITION FILE EX-101.LAB 11 mson-20170331_lab.xml XBRL LABEL FILE Legal Entity [Axis] SonaCare Medical, LLC ("SonaCare") [Member] Range [Axis] Minimum [Member] Cicel (Beijing) Science and Tech Co. Ltd. ("Cicel") [Member] Medtronic Minimally Invasive Therapies ("MMIT") [Member] Geographic Distribution [Axis] International [Member] Type of Arrangement and Non-arrangement Transactions [Axis] License Agreement [Member] Property, Plant and Equipment, Type [Axis] Inventory [Member] Generators [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Award Type [Axis] Stock Options [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Restricted Stock [Member] Related Party [Axis] Chief Executive Officer [Member] Building [Member] Office Equipment & Automobiles [Member] Mr. Stavros G. Vizirgianakis [Member] Applied BioSurgical [Member] Sale of Stock [Axis] Private Placement [Member] Domestic [Member] Mr. Michael A. McManus, Jr. [Member] Retirement Agreement and General Release [Member] Equity Components [Axis] Common Stock [Member] Treasury Stock [Member] Additional paid-in capital [Member] Accumulated deficit [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Former Chinese Distributor - FCPA [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Accounts receivable, less allowance for doubtful accounts of $96,868 and $96,868, respectively Inventories, net Prepaid expenses and other current assets Total current assets Property, plant and equipment, net of accumulated amortization and depreciation of $7,610,152 and $6,976,282, respectively Patents, net of accumulated amortization of $965,996 and $885,394, respectively Goodwill Intangible and other assets Deferred income tax Total assets Liabilities and shareholders' equity Current liabilities: Accounts payable Accrued expenses and other current liabilities Total current liabilities Deferred lease liability Deferred income Total liabilities Commitments and contingencies (Footnote 9) Shareholders' equity: Common stock, .01 par value-shares authorized 20,000,000; 9,162,203 and 7,948,234 shares issued and 9,023,354 and 7,809,385 outstanding in each period, respectively Additional paid-in capital Accumulated deficit Treasury stock, at cost, 138,849 shares in each period Total shareholders' equity Total liabilities and shareholders' equity Allowance for doubtful accounts (in dollars) Accumulated amortization and depreciation (in dollars) Patents, Accumulated amortization (in dollars) Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Net sales Cost of goods sold, exclusive of depreciation from consigned product Gross profit Operating expenses: Selling expenses General and administrative expenses Research and development expenses Total operating expenses Loss from operations Other income (expense): Interest income Royalty income and license fees Other Total other income Loss from operations before income taxes Income tax benefit Loss from continuing operations Discontinued operations: Income from discontinued operations net of tax expense of $88,139 and $85,000 respectively Net income from discontinied operations Net loss from total operations Net loss per share - Basic continuing Operations (in dollars per share) Net loss per share - Diluted continuing operations (in dollars per share) Net income per share - Basic discontinued operations (in dollars per share) Net income per share - Diluted discontinued operations (in dollars per share) Net loss per share - Basic (in dollars per share) Net loss per share - Diluted (in dollars per share) Weighted average shares - Basic (in shares) Weighted average shares - Diluted (in shares) Income from discontinued operations, tax expense Statement [Table] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance at beginning Balance at beginning (in shares) Net loss Sale of common stock Sale of common stock (in shares) Issuance of restricted stock Issuance of restricted stock (in shares) Proceeds from exercise of options Proceeds from exercise of options (in shares) Stock-based compensation Balance at end Balance at end (in shares) Statement of Stockholders' Equity [Abstract] Statement of Cash Flows [Abstract] Operating activities Net loss from continuing operations Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization and other non-cash items Deferred income tax benefit Stock-based compensation Deferred income Deferred lease liability Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses and other assets Accounts payable and accrued expenses Net cash used in operating activities Investing activities Acquisition of property, plant and equipment, net of disposals Acquisition of patents Net cash used in investing activities Financing activities Proceeds from the sale of common stock Proceeds from exercise of stock options Net cash provided by financing activities Cash flows from discontinued operations Net cash provided by investing activities Net cash provided by discontinued operations Net increase / (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Cash paid for income taxes Capitalization of consigned product Accounting Policies [Abstract] Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Inventory Disclosure [Abstract] Inventories Property, Plant and Equipment [Abstract] Property, Plant and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Goodwill Patents Payables and Accruals [Abstract] Accrued Expenses and Other Current Liabilities Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Plans Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Related Party Transactions Income Tax Disclosure [Abstract] Income Taxes Licensing Agreements for Medical Technology Segment Reporting [Abstract] Segment Reporting Severance Severance Basis of Presentation Reclassifications Organization and Business High Intensity Focused Ultrasound Technology Major Customers and Concentration of Credit Risk Use of Estimates Loss per Common Share Recent Accounting Pronouncements Schedule of inventories Schedule of patents Schedule of accrued expenses and other current liabilities Schedule of weighted average fair value at date of grant for options Schedule of summary of option activity Schedule of net sales and accounts receivables Schedule of worldwide revenue Ownership percentage Proceeds from sale of intangible assets Earn-out percentage Proceeds from sale of intangible assets Earn-out percentage Proceeds from sale of intangible assets Sales from continuing operations Percentage of continuing operations Royalty revenue Accounts receivable Excluded from the calculation of Diluted EPS (in shares) Raw material Work-in-process Finished goods Inventory, gross Less valuation reserve Inventory, net Depreciation and amortization Estimated useful lives Depreciation term of property Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] 2017 2018 2019 2020 2021 Thereafter Total Intangible assets estimated useful lives Patents totaled Amortization expense Accrued payroll, payroll taxes and vacation Accrued bonus Accrued commissions Professional fees Deferred income Severance Other Accrued expenses and other current liabilities Risk-free interest rates Expected option life in years Expected stock price volatility Expected dividend yield Outstanding Shares [Roll Forward] Outstanding at beginning Granted Excercised Forfeited Expired Outstanding at ending Vested and exercisable at ending Weighted Average Exercise Price [Roll Forward] Outstanding at beginning Granted Excercised Forfeited Expired Outstanding at ending Vested and exercisable at ending Aggregate Intrinsic Value [Roll Forward] Outstanding at beginning Outstanding at ending Vested and exercisable at ending Compensation cost Unrecognized compensation cost Period of recognition Option Expiration period Option vesting period Weighted average fair value at date of grant (in dollars per share) Number of shares granted Fair value of shares vested Number of non-vested stock options Weighted-average grant-date fair value of non-vested stock options (in dollars per share) Amount of non-vested options forfeited Modified of certain stock options Number of stock issued Description of operating lease expiration term Rent expense Frequency of rent expense Purchase and inventory commitments Payment of insurance retention policy Investigative costs Sales Accounts receivable Number of shares sold Share price (in dollars per share) Proceeds from stock sold Income tax benefit from continuing operations Effective rate Agreement expiration date Percentage royalties on sales of product Revenues for royalties Segments [Axis] Total Number of operating segment Description of annual base salary Non-cash compensation expense Compensation expense to forfeiture of unvested stock options Accrue benefits under employment agreement Carrying value as of the balance sheet date of obligations incurred and payable for severance to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Date which agreement is set to expire, in CCYY-MM format. Refers to the name of a legal entity. Disclosure of basis of presentation policy. It represents the capitalization amount of consigned product. Represent chinese distributor. Refers to the name of a legal entity. Information about business segment. It represents the amount of decrease in stock option plan expense. It represents amount of deferred income during the period. It represents amount of deferred lease liability during the period. Refer to the information about annual base salary. Information about business segment. Represent former chinese distributor. Information related to former president of the company. Information about plant, property and equipement. Disclosure of accounting policy for high intensity focused ultrasound technology. It represents amount of Intangible and other assets during the period. Information related to inventory. Information about agreement. An entire disclosure of licensing agreement for medical technology. Information about name of an legal entity. Information about plant, property and equipement. Description of the frequency of periodic payments (monthly, quarterly, annual). It refers to the percentage of rayalties on sales of product. The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Information related to retirement agreement and general release. The sale of intangible assets percentage of gross revenue received as earn out up to first benchmark during the period. The sale of intangible assets percentage of gross revenue received as earn out up to first benchmark during the period. Tabular disclosure of revenue. The entire disclosure for severance. Refers to the name of a legal entity. It represents the amount of increase (decrease) of non-vested options. Gross number of share options (or share units) granted during the period. The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. It represents the value for non-vested options forfeited. Refers to the name of a legal entity. Number of new stock issued during the period. Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Treasury Stock, Value Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding DeferredIncome DeferredLeaseLiability Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Property, Plant, and Equipment Payments to Acquire Intangible Assets Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net Cash Provided by (Used in) Discontinued Operations Cash and Cash Equivalents, Period Increase (Decrease) Goodwill Disclosure [Text Block] SeveranceDisclosureTextBlock ProceedsFromSaleOfIntangibleAssets1 SaleOfIntangibleAssetsPercentageOfGrossRevenueReceived1 ProceedsFromSaleOfIntangibleAssets2 Inventory, Gross Deferred Revenue, Current AccruedSeveranceCurrent Other Accrued Liabilities, Current Accounts Payable and Accrued Liabilities, Current Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Accounts Receivable, Related Parties, Current EX-101.PRE 12 mson-20170331_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1

Document and Entity Information - shares
9 Months Ended

Mar. 31, 2017

Apr. 28, 2017

Document And Entity Information

Entity Registrant Name MISONIX INC

Entity Central Index Key 0000880432

Document Type 10-Q

Trading Symbol MSON

Document Period End Date Mar. 31, 2017

Amendment Flag false

Current Fiscal Year End Date --06-30

Entity a Well-known Seasoned Issuer No

Entity a Voluntary Filer No

Entity's Reporting Status Current Yes

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 9,023,354

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2017

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mson_DocumentAndEntityInformationAbstract

Namespace Prefix: mson_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1

Consolidated Balance Sheets (unaudited) - USD ($)

Mar. 31, 2017

Jun. 30, 2016

Current assets:

Cash and cash equivalents $ 11,856,503 $ 9,049,327

Accounts receivable, less allowance for doubtful accounts of $96,868 and $96,868, respectively 4,357,156 3,869,427

Inventories, net 4,909,415 5,822,935

Prepaid expenses and other current assets 664,249 530,564

Total current assets 21,787,323 19,272,253

Property, plant and equipment, net of accumulated amortization and depreciation of $7,610,152 and $6,976,282, respectively 3,413,116 2,492,815

Patents, net of accumulated amortization of $965,996 and $885,394, respectively 710,070 604,916

Goodwill 1,701,094 1,701,094

Intangible and other assets 300,341 266,603

Deferred income tax 3,581,551 3,394,690

Total assets 31,493,495 27,732,371

Current liabilities:

Accounts payable 1,433,608 1,402,797

Accrued expenses and other current liabilities 1,994,387 1,887,337

Total current liabilities 3,427,995 3,290,134

Deferred lease liability 9,331 9,262

Deferred income 17,737 31,685

Total liabilities 3,455,063 3,331,081

Commitments and contingencies (Footnote 9)

Shareholders' equity:

Common stock, .01 par value-shares authorized 20,000,000; 9,162,203 and 7,948,234 shares issued and 9,023,354 and 7,809,385 outstanding in each period, respectively 91,622 79,482

Additional paid-in capital 37,410,034 32,502,521

Accumulated deficit (8,363,872) (7,081,361)

Treasury stock, at cost, 138,849 shares in each period (1,099,352) (1,099,352)

Total shareholders' equity 28,038,432 24,401,290

Total liabilities and shareholders' equity $ 31,493,495 $ 27,732,371

X

- Definition
It represents amount of Intangible and other assets during the period.
+ References
No definition available.
+ Details

Name: mson_IntangibleAndOtherAssets

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.26(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 25
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707
+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 15 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1

Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)

Mar. 31, 2017

Jun. 30, 2016

Statement of Financial Position [Abstract]

Allowance for doubtful accounts (in dollars) $ 96,868 $ 96,868

Accumulated amortization and depreciation (in dollars) 7,610,152 6,976,282

Patents, Accumulated amortization (in dollars) $ 965,996 $ 885,394

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

Common stock, shares authorized 20,000,000 20,000,000

Common stock, shares issued 9,162,203 7,948,234

Common stock, shares outstanding 9,023,354 7,809,385

Treasury stock, shares 138,849 138,849

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66008989&loc=d3e5074-111524
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 16 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1

Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Income Statement [Abstract]

Net sales $ 7,177,763 $ 5,426,147 $ 19,379,768 $ 16,716,487

Cost of goods sold, exclusive of depreciation from consigned product 2,112,099 1,859,749 5,842,778 5,578,349

Gross profit 5,065,664 3,566,398 13,536,990 11,138,138

Operating expenses:

Selling expenses 3,587,859 3,319,385 10,184,680 8,967,352

General and administrative expenses 2,484,962 1,515,559 6,504,202 4,994,569

Research and development expenses 465,863 548,278 1,398,311 1,340,339

Total operating expenses 6,538,684 5,383,222 18,087,193 15,302,260

Loss from operations (1,473,020) (1,816,824) (4,550,203) (4,164,122)

Other income (expense):

Interest income 18 19 56 63

Royalty income and license fees 953,235 963,025 2,846,351 2,969,557

Other (6,940) (5,464) (15,576) (16,898)

Total other income 946,313 957,580 2,830,831 2,952,722

Loss from operations before income taxes (526,707) (859,244) (1,719,372) (1,211,400)

Income tax benefit (219,000) (15,000) (275,000) (322,000)

Loss from continuing operations (307,707) (844,244) (1,444,372) (889,400)

Discontinued operations:

Income from discontinued operations net of tax expense of $88,139 and $85,000 respectively 161,861 165,000 161,861 165,000

Net income from discontinied operations 161,861 165,000 161,861 165,000

Net loss from total operations $ (145,846) $ (679,244) $ (1,282,511) $ (724,400)

Net loss per share - Basic continuing Operations (in dollars per share) $ (0.04) $ (0.11) $ (0.17) $ (0.11)

Net loss per share - Diluted continuing operations (in dollars per share) (0.04) (0.11) (0.17) (0.11)

Net income per share - Basic discontinued operations (in dollars per share) 0.02 0.02 0.02 0.02

Net income per share - Diluted discontinued operations (in dollars per share) 0.02 0.02 0.02 0.02

Net loss per share - Basic (in dollars per share) (0.02) (0.09) (0.16) (0.09)

Net loss per share - Diluted (in dollars per share) $ (0.02) $ (0.09) $ (0.16) $ (0.09)

Weighted average shares - Basic (in shares) 8,613,354 7,789,174 8,263,343 7,772,761

Weighted average shares - Diluted (in shares) 8,613,354 7,789,174 8,263,343 7,772,761

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20187-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20187-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65878427&loc=d3e1012-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721523-107759

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4568447-111683

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721525-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65878427&loc=d3e957-107759
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721525-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721523-107759

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65878427&loc=d3e957-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65878427&loc=d3e1012-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(14))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 5.E)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355146-122828

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RoyaltyIncomeNonoperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Expenses recognized in the period that are directly related to the selling and distribution of products or services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SellingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 17 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1

Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)
3 Months Ended 9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Income Statement [Abstract]

Income from discontinued operations, tax expense $ 88,139 $ 85,000 $ 88,139 $ 85,000

X

- Definition
Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65896914&loc=d3e38679-109324

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721523-107759

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32672-109319
+ Details

Name: us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1

Consolidated Statement of Shareholders' Equity (Unaudited) - 9 months ended Mar. 31, 2017 - USD ($)

Common Stock [Member]

Treasury Stock [Member]

Additional paid-in capital [Member]

Accumulated deficit [Member]

Total

Balance at beginning at Jun. 30, 2016 $ 79,482 $ (1,099,352) $ 32,502,521 $ (7,081,361) $ 24,401,290

Balance at beginning (in shares) at Jun. 30, 2016 7,948,234 (138,849)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (1,282,511) (1,282,511)

Sale of common stock $ 7,615 3,992,385 4,000,000

Sale of common stock (in shares) 761,469

Issuance of restricted stock $ 4,000 (4,000)

Issuance of restricted stock (in shares) 400,000

Proceeds from exercise of options $ 525 302,922 $ 303,447

Proceeds from exercise of options (in shares) 52,500 (52,500)

Stock-based compensation 616,206 $ 616,206

Balance at end at Mar. 31, 2017 $ 91,622 $ (1,099,352) $ 37,410,034 $ (8,363,872) $ 28,038,432

Balance at end (in shares) at Mar. 31, 2017 9,162,203 (138,849)

X

- Definition
Number of new stock issued during the period.
+ References
No definition available.
+ Details

Name: mson_StockIssuedDuringPeriodSharesNewIssues1

Namespace Prefix: mson_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
No definition available.
+ Details

Name: mson_StockIssuedDuringPeriodValueNewIssues1

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66904339&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65896087&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65896087&loc=d3e11178-113907
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1

Consolidated Statement of Shareholders' Equity (Parenthetical) - $ / shares

Mar. 31, 2017

Jun. 30, 2016

Statement of Stockholders' Equity [Abstract]

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1

Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Operating activities

Net loss from continuing operations $ (1,444,372) $ (889,400)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization and other non-cash items 763,434 1,271,864

Deferred income tax benefit (186,861) (260,000)

Stock-based compensation 616,206 1,175,165

Deferred income (13,948) (20,852)

Deferred lease liability 69 6,947

Changes in operating assets and liabilities:

Accounts receivable (487,729) 379,689

Inventories (449,986) (2,623,620)

Prepaid expenses and other assets (167,423) (282,221)

Accounts payable and accrued expenses 137,861 141,624

Net cash used in operating activities (1,232,749) (1,100,804)

Investing activities

Acquisition of property, plant and equipment, net of disposals (239,627) (410,561)

Acquisition of patents (185,756) (71,541)

Net cash used in investing activities (425,383) (482,102)

Financing activities

Proceeds from the sale of common stock 4,000,000

Proceeds from exercise of stock options 303,447 151,247

Net cash provided by financing activities 4,303,447 151,247

Cash flows from discontinued operations

Net cash provided by investing activities 161,861 165,000

Net cash provided by discontinued operations 161,861 165,000

Net increase / (decrease) in cash and cash equivalents 2,807,176 (1,266,659)

Cash and cash equivalents at beginning of period 9,049,327 9,623,749

Cash and cash equivalents at end of period 11,856,503 8,357,090

Supplemental disclosure of cash flow information:

Cash paid for income taxes 9,866 141,120

Capitalization of consigned product $ 1,363,506 $ 1,017,506

X

- Definition
It represents the capitalization amount of consigned product.
+ References
No definition available.
+ Details

Name: mson_CapitalizationOfConsignedProduct

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
It represents amount of deferred income during the period.
+ References
No definition available.
+ Details

Name: mson_DeferredIncome

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
It represents amount of deferred lease liability during the period.
+ References
No definition available.
+ Details

Name: mson_DeferredLeaseLiability

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760
+ Details

Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=63044130

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Increase (decrease) in cash associated with the entity's discontinued operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=65897068&loc=SL4591551-111686

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies
9 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies
1. Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies

Basis of Presentation

These consolidated financial statements of Misonix, Inc. (“Misonix” or the “Company”) include the accounts of Misonix and its 100% owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. As such, they should be read with reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which provides a more complete explanation of the Company’s accounting policies, financial position, operating results, business properties and other matters. In the opinion of management, these financial statements reflect all adjustments considered necessary for a fair statement of interim results.

Reclassifications

Certain expenses on the Statement of Operations have been reclassified to be consistent with the current year presentation. Historically, the Company had recorded stock compensation expense and bonus expense predominantly within general and administrative expenses. The Company has reclassified the prior years’ presentation to allocate certain of these costs to cost of goods sold, selling expenses and research and development expenses, which is consistent with the classification being used in fiscal 2017. This reclassification had no impact on the Company’s presentation of operating income (loss) and the gross profit impact was not material.

Organization and Business

Misonix designs, manufactures, develops and markets therapeutic ultrasonic devices. These products are used for precise bone sculpting, removal of soft tumors, and tissue debridement in the fields of orthopedic surgery, plastic surgery, neurosurgery, podiatry and vascular surgery. In the United States, the Company sells its products through a network of commissioned agents assisted by Company personnel. Outside of the United States, the Company sells to distributors who then resell the product to hospitals. The Company operates as one business segment.

High Intensity Focused Ultrasound Technology

The Company sold its rights to the high intensity focused ultrasound technology to SonaCare Medical, LLC (“SonaCare”) in May 2010. The Company may receive up to approximately $5.8 million in payment for the sale. SonaCare will pay the Company 7% of the gross revenues received from its sales of the (i) prostate product in Europe and (ii) kidney and liver products worldwide, until the Company has received payments of $3 million, and thereafter 5% of the gross revenues, up to an aggregate payment of $5.8 million, all subject to a minimum annual royalty of $250,000. Cumulative payments through March 31, 2017 were $1,504,788. Payments are generally received once per year, in the Company’s third fiscal quarter. For the three months ended March 31, 2017 and 2016, the Company received a royalty of $250,000 in each quarter, which has been recorded in discontinued operations.

Major Customers and Concentration of Credit Risk

Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. (“Cicel”) of $0 and $1,337,277 for the nine months ended March 31, 2017 and 2016, respectively, representing 8.0% of sales for 2016. There were no accounts receivable from Cicel at March 31, 2017 and June 30, 2016. The Company terminated its agreement with Cicel in the first quarter of fiscal 2017.

For the three months ended March 31, 2017, one international distributor accounted for approximately 10% of sales for the quarter. In addition, this same customer had outstanding accounts receivable at March 31, 2017 of $369,463.

Total royalties from Medtronic Minimally Invasive Therapies (“MMIT”) related to their sales of the Company’s ultrasonic cutting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $2,838,487 and $2,930,240, for the nine months ended March 31, 2017 and 2016, respectively. Accounts receivable from MMIT royalties were approximately $953,000 and $973,000 at March 31, 2017 and June 30, 2016, respectively. The license agreement with MMIT expires in August 2017.

At March 31, 2017 and June 30, 2016, the Company’s accounts receivable with customers outside the United States were approximately $762,000 and $768,000, respectively, none of which is over 90 days.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for, but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and related valuation allowances, and stock-based compensation. Actual results could differ from those estimates.

Loss per Common Share

Diluted EPS for the three and nine months ended March 31, 2017 and March 31, 2016 as presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. Accordingly, excluded from the calculation of diluted EPS are outstanding options to purchase 145,750 and 512,750 shares of common stock for the three and nine months ended March 31, 2017, and options to purchase 844,250 and 486,000 shares of common stock for the three and nine months ended March 31, 2016.

Recent Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will apply this guidance to applicable impairment tests after January 1, 2017.

In February 2016, the FASB issued guidance on lease accounting requiring lessees to recognize a right-of-use asset and a lease liability for long-term leases. The liability will be equal to the present value of lease payments. This guidance must be applied using a modified retrospective transition approach to all annual and interim periods presented and is effective for the Company beginning in fiscal 2019. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.

In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes (Topic740)”. The amendments in this ASU require deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments eliminate the guidance in Topic 740 that requires an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount in a classified statement of financial position. The Company adopted ASU 2015-17 as of March 31, 2016 on a prospective basis in order to simplify the balance sheet classification of deferred taxes.



In May 2014, the FASB issued guidance on revenue from contracts with customers. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved, in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. This guidance permits the use of either the retrospective or cumulative effect transition method and is effective for the Company beginning in 2019; early adoption is permitted beginning in 2018. The Company has not yet selected a transition method and is currently evaluating the impact of the guidance on the Company's financial condition, results of operations and related disclosures. The FASB has also issued the following additional guidance clarifying certain issues on revenue from contracts with customers: Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients and Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6003-108592
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1

Fair Value of Financial Instruments
9 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments
2. Fair Value of Financial Instruments

We follow a three-level fair value hierarchy that prioritizes the inputs to measure fair value. This hierarchy requires entities to maximize the use of "observable inputs" and minimize the use of "unobservable inputs." The three levels of inputs used to measure fair value are as follows:

Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets as of the measurement date.

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs that reflect assumptions that market participants would use in pricing an asset or liability.

At March 31, 2017 and June 30, 2016, all of our cash, trade accounts receivable and trade accounts payable were short term in nature, and their carrying amounts approximate fair value.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1

Inventories
9 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Inventories
3. Inventories

Inventories are summarized as follows:

March 31, June 30,

2017 2016

Raw material $ 2,481,557 $ 3,102,175

Work-in-process 708,593 854,631

Finished goods 3,004,743 3,101,234

6,194,893 7,058,040

Less valuation reserve 1,285,478 1,235,105

$ 4,909,415 $ 5,822,935

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1

Property, Plant and Equipment
9 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment
4. Property, Plant and Equipment

Depreciation and amortization of property, plant and equipment was $253,515 and $345,355 for the three months ended March 31, 2017 and 2016, respectively, and was $682,832 and $982,984 for the nine months ended March 31, 2017 and 2016, respectively. Inventory items included in property, plant and equipment are depreciated using the straight line method over estimated useful lives of 3 to 5 years. Depreciation of generators which are consigned to customers is expensed over a 5 year period during the nine months ended March 31, 2017 and is expensed over a 3 year period for the nine months ended March 31, 2016, and depreciation is charged to selling expenses. The impact of this change in accounting estimate was a reduction in expense of approximately $533,000 for the nine months ended March 31, 2017, compared to what the expense would have been without this change.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13-14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1

Goodwill
9 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill
5. Goodwill

Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or products. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long term rate of growth for the Company’s business, the useful lives over which cash flows will occur and determination of the Company’s weighted average cost of capital. The Company primarily utilizes the Company’s market capitalization and a discontinued cash flow model in determining the fair value which consists of Level 3 inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. The Company completed its annual goodwill impairment tests for fiscal 2016 and 2015 as of June 30 of each year. No impairment of goodwill was deemed to exist in fiscal 2016 and 2015.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1

Patents
9 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Patents
6. Patents

The costs of acquiring or processing patents are capitalized at cost. These amounts are being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Patents totaled $710,070 and $604,916 at March 31, 2017 and June 30, 2016, respectively. Amortization expense for the three months ended March 31, 2017 and 2016 was $27,877and $23,090, respectively, and for the nine months ended March 31, 2017 and 2016 was $80,602 and $69,897, respectively.

The following is a schedule of estimated future patent amortization expense as of March 31, 2017:

2017 $ 28,239

2018 110,790

2019 102,484

2020 79,055

2021 72,884

Thereafter 316,618

$ 710,070

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1

Accrued Expenses and Other Current Liabilities
9 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities
7. Accrued Expenses and Other Current Liabilities

The following summarizes accrued expenses and other current liabilities:



March 31, June 30,

2017 2016

Accrued payroll, payroll taxes and vacation 676,882 648,705

Accrued bonus 300,000 300,000

Accrued commissions 429,000 433,000

Professional fees 228,584 256,130

Deferred income 29,491 20,655

Severance 99,859 -

Other 230,571 228,847

$ 1,994,387 $ 1,887,337

X

- Definition
The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1

Stock-Based Compensation Plans
9 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation Plans
8. Stock-Based Compensation Plans

Stock Option Awards

For the three and nine months ended March 31, 2017, the compensation cost that has been charged against income for the Company’s stock option plans was $532,341 and $616,206, respectively, which in the nine month period included a charge to modify certain stock options of $81,765 and a reversal of stock compensation from prior periods due to forfeitures of unvested options of $616,239. For the three and nine months ended March 31, 2016, compensation cost that has been charged against income for the Company’s stock option plans was $446,172 and $1,175,000, respectively. As of March 31, 2017, there was approximately $2,771,938 of total unrecognized compensation cost related to non-vested share-based compensation arrangements to be recognized over a weighted-average period of 2.8 years.



Stock options typically expire 10 years from the date of grant and vest over service periods, which typically are 4 years. All options are granted at fair market value, as defined in the applicable plans.

The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. The expected volatility represents the historical price changes of the Company’s stock over a period equal to that of the expected term of the option. The Company uses the simplified method for determining the option term. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The expected dividend yield is based upon historical and projected dividends. The Company has historically not paid dividends, and is not expected to do so in the near term.

The weighted average fair value at date of grant for options granted during the nine months ended March 31, 2017 and 2016 was $4.46 and $4.23, respectively. There were options to purchase 327,500 shares granted during the nine months ended March 31, 2017. The fair value was estimated based on the weighted average assumptions of:

For nine months ended March 31,

2017 2016

Risk-free interest rates 1.80 % 1.71 %

Expected option life in years 6.25 6.25

Expected stock price volatility 54.68 % 55.41 %

Expected dividend yield 0 % 0 %

A summary of option activity under the Company’s equity plans as of March 31, 2017, and changes during the nine months ended March 31, 2017 is presented below:

Outstanding
Shares Average
Exercise
Price Aggregate
Instrinsic Value

Vested and exercisable at June 30, 2016 1,790,224 $ 6.38 $ 1,675,072

Granted 327,500 $ 8.34

Exercised (52,500 ) $ 5.78

Forfeited (376,625 ) $ 8.24

Expired (2,700 ) $ 3.45

Outstanding as of March 31, 2017 1,685,899 $ 6.37 $ 9,324,182

Vested and exercisable at March 31, 2017 980,774 $ 4.63 $ 7,097,409

The total fair value of shares vested during the nine months ended March 31, 2017 was $1,055,434. The number and weighted-average grant-date fair value of non-vested stock options at the beginning of fiscal 2017 was 976,875 and $4.81, respectively. The number and weighted-average grant-date fair value of stock options which vested during the nine months ended March 31, 2017 was 224,250 and $4.71, respectively.

Restricted Stock Awards

On December 15, 2016, the Company issued 400,000 shares of restricted stock to its Chief Executive Officer. These awards vest over a period of up to five years, subject to meeting certain service, performance and market conditions. These awards were valued at approximately $3.4 million and compensation expense recorded in the three and nine months ended March 31, 2017 was $224,498 and $265,063, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.
+ References
No definition available.
+ Details

Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1

Commitments and Contingencies
9 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
9. Commitments and Contingencies

Leases

The Company has entered into several non-cancellable operating leases for the rental of certain manufacturing and office space, equipment and automobiles expiring in various years through 2021. The principal building lease provides for a monthly rental of approximately $26,000. The Company also leases certain office equipment and automobiles under operating leases expiring through fiscal 2018.

Class Action Securities Litigation

On September 19, 2016, Richard Scalfani, an individual shareholder of Misonix, filed a lawsuit against the Company and its former CEO and CFO in the U.S. District Court for the Eastern District of New York, alleging violations of the federal securities laws. The complaint alleges that the Company’s stock price was artificially inflated between November 5, 2015 and September 14, 2016 as a result of alleged false and misleading statements in the Company’s securities filings concerning the Company’s business, operations, and prospects and the Company’s internal control over financial reporting. Scalfani filed the action seeking to represent a putative class of all persons (other than defendants, officers and directors of the Company, and their affiliates) who purchased publicly traded Misonix securities between November 5, 2015 and September 14, 2016. Scalfani seeks an unspecified amount of damages for himself and for the putative class under the federal securities laws. On March 24, 2017, the Court appointed Scalfani and another individual Misonix shareholder, Tracey Angiuoli, as lead plaintiffs for purposes of pursuing the action on behalf of the putative class. The Company believes it has various legal and factual defenses to the allegations in the complaint, and intends to vigorously defend the action. The case is at its earliest stages; there has been no discovery and there is no trial date. The Company is not able to estimate the amount of potential loss it may recognize, if any, from this claim. The Company believes that its insurance coverage is sufficient to cover a potential loss, after payment of the policy retention of $250,000.

Former Chinese Distributor - FCPA

For several months, with the assistance of outside counsel, the Company conducted a voluntary investigation into the business practices of the independent Chinese entity that previously distributed its products in China and the Company’s knowledge of those business practices, which may have implications under the FCPA, as well as into various internal controls issues identified during the investigation.

On September 27, 2016 and September 28, 2016, we voluntarily contacted the SEC and the DOJ, respectively, to advise both agencies of these potential issues. The Company has provided and will continue to provide documents and other information to the SEC and the DOJ, and is cooperating fully with these agencies in their investigations of these matters.

Although the Company’s investigation is complete, additional issues or facts could arise which may expand the scope or severity of the potential violations. The Company has no current information derived from the investigation or otherwise to suggest that its previously reported financial statements and results are incorrect.

At this stage, the Company is unable to predict what, if any, action the DOJ or the SEC may take or what, if any, penalties or remedial measures these agencies may seek. Nor can the Company predict the impact on the Company as a result of these matters, which may include the imposition of fines, civil and criminal penalties, which are not currently estimable, as well as equitable remedies, including disgorgement of any profits earned from improper conduct and injunctive relief, limitations on the Company’s conduct, and the imposition of a compliance monitor. The DOJ and the SEC periodically have based the amount of a penalty or disgorgement in connection with an FCPA action, at least in part, on the amount of profits that a company obtained from the business in which the violations of the FCPA occurred. During its distributorship relationship with the prior Chinese distributor from 2010 through 2016, the Company generated sales of approximately $8 million from the relationship.

Further, the Company may suffer other civil penalties or adverse impacts, including lawsuits by private litigants in addition to the lawsuit that has already been filed, or investigations and fines imposed by local authorities. The investigative costs to date are approximately $2.1 million, of which approximately $2.0 million was charged to general and administrative expenses during the nine months ended March 31, 2017. Investigative costs for the three months ended March 31, 2017 were approximately $650,000.



Former Chinese Distributor – Litigation

On April 5, 2017, the Company’s former distributor in China, Cicel (Beijing) Science & Technology Co., Ltd., filed a lawsuit against the Company and certain officers and directors of the Company in the United States District Court for the Eastern District of New York, alleging that the Company improperly terminated its contract with the former distributor. The complaint, which seeks various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, asserts various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. The Company believes it has various legal and factual defenses to the allegations in the complaint, and intends to vigorously defend the action. The case is at its earliest stages; there has been no discovery and there is no trial date.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1

Related Party Transactions
9 Months Ended

Mar. 31, 2017

Related Party Transactions [Abstract]

Related Party Transactions
10. Related Party Transactions

Applied BioSurgical, a company owned by the brother of the Company’s Chief Executive Officer, Stavros G. Vizirgianakis, is an independent distributor for the Company outside of the United States.

Set forth below is a table showing the Company’s net sales for the nine months ended March 31 and accounts receivable at March 31 for the indicated time periods below with Applied BioSurgical:

2017 2016

Sales $ 367,592 $ 349,490

Accounts receivable $ 104,678 $ 212,981

On October 25, 2016, the Company sold 761,469 shares of Common Stock in a private placement to Stavros G. Vizirgianakis, the Company’s current Chief Executive Officer, at a price per share of $5.253, representing total cash proceeds to the Company of approximately $4.0 million.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1

Income Taxes
9 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes
11. Income Taxes

For the three months ended March 31, 2017 and 2016, the Company recorded an income tax benefit from continuing operations of $219,000 and $15,000, respectively, and for the nine months ended March 31, 2017 and 2016, the Company recorded an income tax benefit from continuing operations of $275,000 and $322,000, respectively.

For the nine months ended March 31, 2017 and 2016, the effective rate of 16.0% and 26.6%, respectively, on continuing operations varied from the U.S. federal statutory rate primarily due to permanent book tax differences relating principally to stock compensation expense and tax credits.

As of March 31, 2017 and June 30, 2016, the Company has no material unrecognized tax benefits or accrued interest and penalties.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1

Licensing Agreements for Medical Technology
9 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Licensing Agreements for Medical Technology
12. Licensing Agreements for Medical Technology

In October 1996, the Company entered into a License Agreement with MMIT expiring August 2017, covering the further development and commercial exploitation of the Company's medical technology relating to laparoscopic products, which uses high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery. The MMIT license provides for exclusive worldwide marketing and sales rights for this technology. The Company receives a 5% royalty on sales of these products by MMIT. Royalties from this license agreement were $953,235 and $956,947 for the three months ended March 31, 2017 and 2016, respectively, and were $2,838,487 and $2,932,240 for the nine months ended March 31, 2017 and 2016, respectively.

X

- Definition
An entire disclosure of licensing agreement for medical technology.
+ References
No definition available.
+ Details

Name: mson_LicensingAgreementsForMedicalTechnologyTextBlock

Namespace Prefix: mson_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1

Segment Reporting
9 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment Reporting
13. Segment Reporting

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision-maker (“CODM") in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company has concluded that its Chief Executive Officer is the CODM as he is the ultimate decision maker for key operating decisions, determining the allocation of resources and assessing the financial performance of the Company. These decisions, allocations and assessments are performed by the CODM using consolidated financial information. Consolidated financial information is utilized by the CODM as the Company's current product offering primarily consists of minimally invasive therapeutic ultrasonic medical devices. The Company's products are relatively consistent and manufacturing is centralized and consistent across product offerings. Based on these factors, key operating decisions and resource allocations are made by the CODM using consolidated financial data and as such the Company has concluded that it operates as one segment.



Worldwide revenue for the Company's products is categorized as follows:

For the Nine Months Ended

March 31

2017 2016

Domestic $ 12,019,103 $ 9,324,928

International 7,360,665 7,391,559

Total $ 19,379,768 $ 16,716,487

Substantially all of the Company’s long-lived assets are located in the United States.

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1

Severance
9 Months Ended

Mar. 31, 2017

Severance

Severance
14. Severance

On August 26, 2016, the Company and the Company’s former Chief Executive Officer, Michael McManus (“McManus”) entered into a retirement agreement and general release (the “Retirement Agreement”). Pursuant to the Retirement Agreement, on September 2, 2016 Mr. McManus resigned as a Director and the Chairman of the Board of Directors of the Company and retired as President and Chief Executive Officer of the Company. Pursuant to the Retirement Agreement, the Company agreed to (i) pay Mr. McManus’ salary through June 30, 2017 at the then current level; (ii) continue to pay premiums for Mr. McManus’ and his dependents’ coverage under the Company’s medical, dental, vision, hospitalization, long term care and life insurance coverage through June 30, 2017 at the then current levels upon timely election by Mr. McManus under the law informally known as COBRA; and (iii) extend the exercisability of previously granted and then currently vested options to purchase shares of Common Stock through June 30, 2017. In addition, Mr. McManus had continued use of the vehicle provided him pursuant to his prior employment agreement through December 31, 2016. In connection with this Retirement Agreement, the Company recorded a charge of $330,000 during the quarter ended September 30, 2016 to accrue for the cash portion of these benefits, which will be paid during the period ending June 30, 2017. In addition, the Company recorded a non-cash compensation expense of $61,000 in connection with the modification of the terms of his vested stock options, and recorded a reduction in non-cash compensation expense of $596,000 relating to the forfeiture of his unvested stock options.

X

- References
No definition available.
+ Details

Name: mson_SeveranceAbstract

Namespace Prefix: mson_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for severance.
+ References
No definition available.
+ Details

Name: mson_SeveranceDisclosureTextBlock

Namespace Prefix: mson_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Policies)
9 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation

These consolidated financial statements of Misonix, Inc. (“Misonix” or the “Company”) include the accounts of Misonix and its 100% owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. As such, they should be read with reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which provides a more complete explanation of the Company’s accounting policies, financial position, operating results, business properties and other matters. In the opinion of management, these financial statements reflect all adjustments considered necessary for a fair statement of interim results.

Reclassifications
Reclassifications

Certain expenses on the Statement of Operations have been reclassified to be consistent with the current year presentation. Historically, the Company had recorded stock compensation expense and bonus expense predominantly within general and administrative expenses. The Company has reclassified the prior years’ presentation to allocate certain of these costs to cost of goods sold, selling expenses and research and development expenses, which is consistent with the classification being used in fiscal 2017. This reclassification had no impact on the Company’s presentation of operating income (loss) and the gross profit impact was not material.

Organization and Business
Organization and Business

Misonix designs, manufactures, develops and markets therapeutic ultrasonic devices. These products are used for precise bone sculpting, removal of soft tumors, and tissue debridement in the fields of orthopedic surgery, plastic surgery, neurosurgery, podiatry and vascular surgery. In the United States, the Company sells its products through a network of commissioned agents assisted by Company personnel. Outside of the United States, the Company sells to distributors who then resell the product to hospitals. The Company operates as one business segment.

High Intensity Focused Ultrasound Technology
High Intensity Focused Ultrasound Technology

The Company sold its rights to the high intensity focused ultrasound technology to SonaCare Medical, LLC (“SonaCare”) in May 2010. The Company may receive up to approximately $5.8 million in payment for the sale. SonaCare will pay the Company 7% of the gross revenues received from its sales of the (i) prostate product in Europe and (ii) kidney and liver products worldwide, until the Company has received payments of $3 million, and thereafter 5% of the gross revenues, up to an aggregate payment of $5.8 million, all subject to a minimum annual royalty of $250,000. Cumulative payments through March 31, 2017 were $1,504,788. Payments are generally received once per year, in the Company’s third fiscal quarter. For the three months ended March 31, 2017 and 2016, the Company received a royalty of $250,000 in each quarter, which has been recorded in discontinued operations.

Major Customers and Concentration of Credit Risk
Major Customers and Concentration of Credit Risk

Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. (“Cicel”) of $0 and $1,337,277 for the nine months ended March 31, 2017 and 2016, respectively, representing 8.0% of sales for 2016. There were no accounts receivable from Cicel at March 31, 2017 and June 30, 2016. The Company terminated its agreement with Cicel in the first quarter of fiscal 2017.

For the three months ended March 31, 2017, one international distributor accounted for approximately 10% of sales for the quarter. In addition, this same customer had outstanding accounts receivable at March 31, 2017 of $369,463.

Total royalties from Medtronic Minimally Invasive Therapies (“MMIT”) related to their sales of the Company’s ultrasonic cutting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $2,838,487 and $2,930,240, for the nine months ended March 31, 2017 and 2016, respectively. Accounts receivable from MMIT royalties were approximately $953,000 and $973,000 at March 31, 2017 and June 30, 2016, respectively. The license agreement with MMIT expires in August 2017.

At March 31, 2017 and June 30, 2016, the Company’s accounts receivable with customers outside the United States were approximately $762,000 and $768,000, respectively, none of which is over 90 days.

Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for, but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and related valuation allowances, and stock-based compensation. Actual results could differ from those estimates.

Loss per Common Share
Loss per Common Share

Diluted EPS for the three and nine months ended March 31, 2017 and March 31, 2016 as presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. Accordingly, excluded from the calculation of diluted EPS are outstanding options to purchase 145,750 and 512,750 shares of common stock for the three and nine months ended March 31, 2017, and options to purchase 844,250 and 486,000 shares of common stock for the three and nine months ended March 31, 2016.

Recent Accounting Pronouncements
Recent Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will apply this guidance to applicable impairment tests after January 1, 2017.

In February 2016, the FASB issued guidance on lease accounting requiring lessees to recognize a right-of-use asset and a lease liability for long-term leases. The liability will be equal to the present value of lease payments. This guidance must be applied using a modified retrospective transition approach to all annual and interim periods presented and is effective for the Company beginning in fiscal 2019. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.

In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes (Topic740)”. The amendments in this ASU require deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments eliminate the guidance in Topic 740 that requires an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount in a classified statement of financial position. The Company adopted ASU 2015-17 as of March 31, 2016 on a prospective basis in order to simplify the balance sheet classification of deferred taxes.



In May 2014, the FASB issued guidance on revenue from contracts with customers. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved, in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. This guidance permits the use of either the retrospective or cumulative effect transition method and is effective for the Company beginning in 2019; early adoption is permitted beginning in 2018. The Company has not yet selected a transition method and is currently evaluating the impact of the guidance on the Company's financial condition, results of operations and related disclosures. The FASB has also issued the following additional guidance clarifying certain issues on revenue from contracts with customers: Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients and Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements.

There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

X

- Definition
Disclosure of basis of presentation policy.
+ References
No definition available.
+ Details

Name: mson_BasisOfPresentationPolicyTextBlock

Namespace Prefix: mson_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for high intensity focused ultrasound technology.
+ References
No definition available.
+ Details

Name: mson_HighIntensityFocusedUltrasoundTechnologyPolicyTextBlock

Namespace Prefix: mson_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6404-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6351-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6327-108592
+ Details

Name: us-gaap_MajorCustomersPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6003-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=64851502&loc=SL51803626-108592
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755
+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6132-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1

Inventories (Tables)
9 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Schedule of inventories
Inventories are summarized as follows:

March 31, June 30,

2017 2016

Raw material $ 2,481,557 $ 3,102,175

Work-in-process 708,593 854,631

Finished goods 3,004,743 3,101,234

6,194,893 7,058,040

Less valuation reserve 1,285,478 1,235,105

$ 4,909,415 $ 5,822,935

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1

Patents (Tables)
9 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of patents
The following is a schedule of estimated future patent amortization expense as of March 31, 2017:

2017 $ 28,239

2018 110,790

2019 102,484

2020 79,055

2021 72,884

Thereafter 316,618

$ 710,070

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1

Accrued Expenses and Other Current Liabilities (Tables)
9 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Schedule of accrued expenses and other current liabilities
The following summarizes accrued expenses and other current liabilities:



March 31, June 30,

2017 2016

Accrued payroll, payroll taxes and vacation 676,882 648,705

Accrued bonus 300,000 300,000

Accrued commissions 429,000 433,000

Professional fees 228,584 256,130

Deferred income 29,491 20,655

Severance 99,859 -

Other 230,571 228,847

$ 1,994,387 $ 1,887,337

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1

Stock-Based Compensation Plans (Tables)
9 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of weighted average fair value at date of grant for options
The fair value was estimated based on the weighted average assumptions of:

For nine months ended March 31,

2017 2016

Risk-free interest rates 1.80 % 1.71 %

Expected option life in years 6.25 6.25

Expected stock price volatility 54.68 % 55.41 %

Expected dividend yield 0 % 0 %

Schedule of summary of option activity
A summary of option activity under the Company’s equity plans as of March 31, 2017, and changes during the nine months ended March 31, 2017 is presented below:

Outstanding
Shares Average
Exercise
Price Aggregate
Instrinsic Value

Vested and exercisable at June 30, 2016 1,790,224 $ 6.38 $ 1,675,072

Granted 327,500 $ 8.34

Exercised (52,500 ) $ 5.78

Forfeited (376,625 ) $ 8.24

Expired (2,700 ) $ 3.45

Outstanding as of March 31, 2017 1,685,899 $ 6.37 $ 9,324,182

Vested and exercisable at March 31, 2017 980,774 $ 4.63 $ 7,097,409

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in stock options.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1

Related Party Transactions (Tables)
9 Months Ended

Mar. 31, 2017

Related Party Transactions [Abstract]

Schedule of net sales and accounts receivables
Set forth below is a table showing the Company’s net sales for the nine months ended March 31 and accounts receivable at March 31 for the indicated time periods below with Applied BioSurgical:

2017 2016

Sales $ 367,592 $ 349,490

Accounts receivable $ 104,678 $ 212,981

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1

Segment Reporting (Tables)
9 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Schedule of worldwide revenue
Worldwide revenue for the Company's products is categorized as follows:

For the Nine Months Ended

March 31

2017 2016

Domestic $ 12,019,103 $ 9,324,928

International 7,360,665 7,391,559

Total $ 19,379,768 $ 16,716,487

X

- Definition
Tabular disclosure of revenue.
+ References
No definition available.
+ Details

Name: mson_ScheduleOfRevenueTableTextBlock

Namespace Prefix: mson_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

May 10, 2010

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Jun. 30, 2016

Ownership percentage 100.00% 100.00%

Sales from continuing operations $ 7,177,763 $ 5,426,147 $ 19,379,768 $ 16,716,487

Excluded from the calculation of Diluted EPS (in shares) 145,750 844,250 512,750 486,000

International [Member]

Sales from continuing operations $ 7,360,665 $ 7,391,559

Accounts receivable $ 762,000 762,000 $ 768,000

SonaCare Medical, LLC ("SonaCare") [Member]

Proceeds from sale of intangible assets $ 5,800,000 1,504,788

Earn-out percentage 7.00%

Proceeds from sale of intangible assets $ 3,000,000

Earn-out percentage 5.00%

Proceeds from sale of intangible assets $ 5,800,000

Royalty revenue $ 250,000 $ 250,000

SonaCare Medical, LLC ("SonaCare") [Member] | Minimum [Member]

Royalty revenue $ 250,000

Cicel (Beijing) Science and Tech Co. Ltd. ("Cicel") [Member]

Sales from continuing operations 0 $ 1,337,277

Percentage of continuing operations 10.00% 8.00%

Accounts receivable $ 369,463 369,463 0

Medtronic Minimally Invasive Therapies ("MMIT") [Member]

Accounts receivable 953,000 953,000 $ 973,000

Medtronic Minimally Invasive Therapies ("MMIT") [Member] | License Agreement [Member]

Royalty revenue $ 953,235 $ 956,947 $ 2,838,487 $ 2,932,240

X

- Definition
The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
No definition available.
+ Details

Name: mson_ProceedsFromSaleOfIntangibleAssets1

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
No definition available.
+ Details

Name: mson_ProceedsFromSaleOfIntangibleAssets2

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The sale of intangible assets percentage of gross revenue received as earn out up to first benchmark during the period.
+ References
No definition available.
+ Details

Name: mson_SaleOfIntangibleAssetsPercentageOfGrossRevenueReceived

Namespace Prefix: mson_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The sale of intangible assets percentage of gross revenue received as earn out up to first benchmark during the period.
+ References
No definition available.
+ Details

Name: mson_SaleOfIntangibleAssetsPercentageOfGrossRevenueReceived1

Namespace Prefix: mson_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(9))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_AccountsReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_ProceedsFromSaleOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=mson_SonaCareMedicalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=mson_CicelScienceAndTechCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=mson_MedtronicMinimallyInvasiveTherapiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=mson_LicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1

Inventories (Details) - USD ($)

Mar. 31, 2017

Jun. 30, 2016

Inventory Disclosure [Abstract]

Raw material $ 2,481,557 $ 3,102,175

Work-in-process 708,593 854,631

Finished goods 3,004,743 3,101,234

Inventory, gross 6,194,893 7,058,040

Less valuation reserve 1,285,478 1,235,105

Inventory, net $ 4,909,415 $ 5,822,935

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1

Property, Plant and Equipment (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Depreciation and amortization $ 253,515 $ 345,355 $ 682,832 $ 982,984

Inventory [Member]

Estimated useful lives
3 to 5 years

Generators [Member]

Depreciation and amortization $ 533,000

Depreciation term of property 5 years 3 years

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223
+ Details

Name: us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mson_InventoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mson_GeneratorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1

Patents (Details) - USD ($)

Mar. 31, 2017

Jun. 30, 2016

Finite-Lived Intangible Assets [Line Items]

Total $ 710,070 $ 604,916

Patents [Member]

Finite-Lived Intangible Assets [Line Items]

2017 28,239

2018 110,790

2019 102,484

2020 79,055

2021 72,884

Thereafter 316,618

Total $ 710,070 $ 604,916

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1

Patents (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Jun. 30, 2016

Patents totaled $ 710,070 $ 710,070 $ 604,916

Patents [Member]

Intangible assets estimated useful lives 17 years

Patents totaled 710,070 $ 710,070 $ 604,916

Amortization expense $ 27,877 $ 23,090 $ 80,602 $ 69,897

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1

Accrued Expenses and Other Current Liabilities (Details) - USD ($)

Mar. 31, 2017

Jun. 30, 2016

Payables and Accruals [Abstract]

Accrued payroll, payroll taxes and vacation $ 676,882 $ 648,705

Accrued bonus 300,000 300,000

Accrued commissions 429,000 433,000

Professional fees 228,584 256,130

Deferred income 29,491 20,655

Severance 99,859

Other 230,571 228,847

Accrued expenses and other current liabilities $ 1,994,387 $ 1,887,337

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for severance to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: mson_AccruedSeveranceCurrent

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedBonusesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677
+ Details

Name: us-gaap_AccruedPayrollTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details

Name: us-gaap_AccruedSalesCommissionCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1

Stock-Based Compensation Plans (Details)
9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Risk-free interest rates 1.80% 1.71%

Expected option life in years 6 years 3 months 6 years 3 months

Expected stock price volatility 54.68% 55.41%

Expected dividend yield 0.00% 0.00%

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 49 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1

Stock-Based Compensation Plans (Details 1)
9 Months Ended

Mar. 31, 2017

USD ($)

$ / shares

shares

Outstanding Shares [Roll Forward]

Outstanding at beginning | shares 1,790,224

Granted | shares 327,500

Excercised | shares (52,500)

Forfeited | shares (376,625)

Expired | shares (2,700)

Outstanding at ending | shares 1,685,899

Vested and exercisable at ending | shares 980,774

Weighted Average Exercise Price [Roll Forward]

Outstanding at beginning | $ / shares $ 6.38

Granted | $ / shares 8.34

Excercised | $ / shares 5.78

Forfeited | $ / shares 8.24

Expired | $ / shares 3.45

Outstanding at ending | $ / shares 6.37

Vested and exercisable at ending | $ / shares $ 4.63

Aggregate Intrinsic Value [Roll Forward]

Outstanding at beginning | $ $ 1,675,072

Outstanding at ending | $ 9,324,182

Vested and exercisable at ending | $ $ 7,097,409

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 50 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1

Stock-Based Compensation Plans (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Dec. 15, 2016

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Jun. 30, 2017

Compensation cost $ 532,341 $ 446,172 $ 616,206 $ 1,175,165

Unrecognized compensation cost 2,771,938 $ 2,771,938

Period of recognition 2 years 9 months 18 days

Weighted average fair value at date of grant (in dollars per share) $ 4.46 $ 4.23

Number of shares granted 327,500

Fair value of shares vested $ 1,055,434

Number of non-vested stock options 224,250

Weighted-average grant-date fair value of non-vested stock options (in dollars per share) $ 4.71

Amount of non-vested options forfeited $ 616,239

Modified of certain stock options $ 81,765

Subsequent Event [Member]

Number of non-vested stock options 976,875

Weighted-average grant-date fair value of non-vested stock options (in dollars per share) $ 4.81

Stock Options [Member]

Option Expiration period 10 years

Option vesting period 4 years

Restricted Stock [Member] | Chief Executive Officer [Member]

Compensation cost $ 224,498 $ 265,063

Option vesting period 5 years

Fair value of shares vested $ 3,400,000

Number of stock issued 400,000

X

- Definition
It represents the amount of increase (decrease) of non-vested options.
+ References
No definition available.
+ Details

Name: mson_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAmountPeriodIncreaseDecrease

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: mson_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross1

Namespace Prefix: mson_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
No definition available.
+ Details

Name: mson_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1

Namespace Prefix: mson_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
It represents the value for non-vested options forfeited.
+ References
No definition available.
+ Details

Name: mson_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedAmount

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1

Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Payment of insurance retention policy $ 250,000

Net sales $ 7,177,763 $ 5,426,147 19,379,768 $ 16,716,487

Former Chinese Distributor - FCPA [Member]

Investigative costs $ 650,000 2,100,000

Net sales 8,000,000

General and Administrative Expense [Member] | Former Chinese Distributor - FCPA [Member]

Investigative costs 2,000,000

Building [Member]

Rent expense $ 26,000

Frequency of rent expense Monthly

Office Equipment & Automobiles [Member]

Description of operating lease expiration term

Expiring through fiscal 2018.

X

- Definition
Description of the frequency of periodic payments (monthly, quarterly, annual).
+ References
No definition available.
+ Details

Name: mson_OperatingLeasesFrequencyRentExpense

Namespace Prefix: mson_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4) restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 1)
-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6452660&loc=d3e36991-112694
+ Details

Name: us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717
+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Stated amount that is the upper retention limit per entity policy.
+ References
No definition available.
+ Details

Name: us-gaap_ReinsuranceRetentionPolicyAmountRetained

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=mson_FormerChineseDistributorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mson_OfficeEquipmentAndAutomobilesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1

Related Party Transactions (Details) - Mr. Stavros G. Vizirgianakis [Member] - Applied BioSurgical [Member] - USD ($)
9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Sales $ 367,592 $ 349,490

Accounts receivable $ 104,678 $ 212,981

X

- Definition
Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864
+ Details

Name: us-gaap_AccountsReceivableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Related Parties
-URI http://asc.fasb.org/extlink&oid=16382449

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999
+ Details

Name: us-gaap_RevenueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=mson_AppliedBioSurgicalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1

Related Party Transactions (Details Narrative) - Mr. Stavros G. Vizirgianakis [Member] - Private Placement [Member]

Oct. 25, 2016

USD ($)

$ / shares

shares

Number of shares sold | shares 761,469

Share price (in dollars per share) | $ / shares $ 5.253

Proceeds from stock sold | $ $ 4,000,000

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R42.htm IDEA: XBRL DOCUMENT v3.7.0.1

Income Taxes (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Income tax benefit from continuing operations $ 219,000 $ 15,000 $ 275,000 $ 322,000

Effective rate 16.00% 26.60%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 55 R43.htm IDEA: XBRL DOCUMENT v3.7.0.1

Licensing Agreements for Medical Technology (Details Narrative) - License Agreement [Member] - Medtronic Minimally Invasive Therapies ("MMIT") [Member] - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Oct. 31, 1996

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Agreement expiration date 2017-08

Percentage royalties on sales of product 5.00%

Revenues for royalties $ 953,235 $ 956,947 $ 2,838,487 $ 2,932,240

X

- Definition
Date which agreement is set to expire, in CCYY-MM format.
+ References
No definition available.
+ Details

Name: mson_AgreementExpirationDate

Namespace Prefix: mson_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
It refers to the percentage of rayalties on sales of product.
+ References
No definition available.
+ Details

Name: mson_PercentageRoyaltiesOnSalesOfProduct

Namespace Prefix: mson_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=mson_LicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=mson_MedtronicMinimallyInvasiveTherapiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R44.htm IDEA: XBRL DOCUMENT v3.7.0.1

Segment Reporting (Details) - USD ($)
3 Months Ended 9 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Total $ 7,177,763 $ 5,426,147 $ 19,379,768 $ 16,716,487

Domestic [Member]

Total 12,019,103 9,324,928

International [Member]

Total $ 7,360,665 $ 7,391,559

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R45.htm IDEA: XBRL DOCUMENT v3.7.0.1

Segment Reporting (Details Narrative)
9 Months Ended

Mar. 31, 2017

N

Segment Reporting [Abstract]

Number of operating segment 1

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1

Severance (Details Narrative) - Mr. Michael A. McManus, Jr. [Member] - Retirement Agreement and General Release [Member] - USD ($)
3 Months Ended 9 Months Ended

Aug. 26, 2016

Sep. 30, 2016

Mar. 31, 2017

Description of annual base salary
the Company agreed to (i) pay Mr. McManus’ salary through June 30, 2017 at the then current level; (ii) continue to pay premiums for Mr. McManus’ and his dependents’ coverage under the Company’s medical, dental, vision, hospitalization, long term care and life insurance coverage through June 30, 2017 at the then current levels upon timely election by Mr. McManus under the law informally known as COBRA; and (iii) extend the exercisability of previously granted and then currently vested options to purchase shares of Common Stock through June 30, 2017.

Non-cash compensation expense $ 61,000

Compensation expense to forfeiture of unvested stock options $ 596,000

Accrue benefits under employment agreement $ 330,000

X

- Definition
It represents the amount of decrease in stock option plan expense.
+ References
No definition available.
+ Details

Name: mson_DecreaseInStockOptionPlanExpense

Namespace Prefix: mson_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Refer to the information about annual base salary.
+ References
No definition available.
+ Details

Name: mson_DescriptionOfAnnualBaseSalary

Namespace Prefix: mson_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(10)
-URI http://asc.fasb.org/extlink&oid=65897934&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747
+ Details

Name: us-gaap_SeveranceCosts1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mson_FormerPresidentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=mson_RetirementAgreementAndGeneralReleaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 60 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 71 210 1 false 27 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://misonix.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (unaudited) Sheet http://misonix.com/role/BalanceSheets Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://misonix.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://misonix.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://misonix.com/role/StatementsOfOperationsParenthetical Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statement of Shareholders' Equity (Unaudited) Sheet http://misonix.com/role/StatementOfShareholdersEquity Consolidated Statement of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statement of Shareholders' Equity (Parenthetical) Sheet http://misonix.com/role/StatementOfShareholdersEquityParenthetical Consolidated Statement of Shareholders' Equity (Parenthetical) Statements 7 false false R8.htm 00000008 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://misonix.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 00000009 - Disclosure - Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies Sheet http://misonix.com/role/BasisOfPresentationOrganizationAndBusinessAndSummaryOfSignificantAccountingPolicies Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Fair Value of Financial Instruments Sheet http://misonix.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 00000011 - Disclosure - Inventories Sheet http://misonix.com/role/Inventories Inventories Notes 11 false false R12.htm 00000012 - Disclosure - Property, Plant and Equipment Sheet http://misonix.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 12 false false R13.htm 00000013 - Disclosure - Goodwill Sheet http://misonix.com/role/Goodwill Goodwill Notes 13 false false R14.htm 00000014 - Disclosure - Patents Sheet http://misonix.com/role/Patents Patents Notes 14 false false R15.htm 00000015 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://misonix.com/role/AccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 15 false false R16.htm 00000016 - Disclosure - Stock-Based Compensation Plans Sheet http://misonix.com/role/Stock-basedCompensationPlans Stock-Based Compensation Plans Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://misonix.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Related Party Transactions Sheet http://misonix.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 00000019 - Disclosure - Income Taxes Sheet http://misonix.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 00000020 - Disclosure - Licensing Agreements for Medical Technology Sheet http://misonix.com/role/LicensingAgreementsForMedicalTechnology Licensing Agreements for Medical Technology Notes 20 false false R21.htm 00000021 - Disclosure - Segment Reporting Sheet http://misonix.com/role/SegmentReporting Segment Reporting Notes 21 false false R22.htm 00000022 - Disclosure - Severance Sheet http://misonix.com/role/Severance Severance Notes 22 false false R23.htm 00000023 - Disclosure - Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Policies) Sheet http://misonix.com/role/BasisOfPresentationOrganizationAndBusinessAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Policies) Policies http://misonix.com/role/BasisOfPresentationOrganizationAndBusinessAndSummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Inventories (Tables) Sheet http://misonix.com/role/InventoriesTables Inventories (Tables) Tables http://misonix.com/role/Inventories 24 false false R25.htm 00000025 - Disclosure - Patents (Tables) Sheet http://misonix.com/role/PatentsTables Patents (Tables) Tables http://misonix.com/role/Patents 25 false false R26.htm 00000026 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://misonix.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://misonix.com/role/AccruedExpensesAndOtherCurrentLiabilities 26 false false R27.htm 00000027 - Disclosure - Stock-Based Compensation Plans (Tables) Sheet http://misonix.com/role/Stock-basedCompensationPlansTables Stock-Based Compensation Plans (Tables) Tables http://misonix.com/role/Stock-basedCompensationPlans 27 false false R28.htm 00000028 - Disclosure - Related Party Transactions (Tables) Sheet http://misonix.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://misonix.com/role/RelatedPartyTransactions 28 false false R29.htm 00000029 - Disclosure - Segment Reporting (Tables) Sheet http://misonix.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://misonix.com/role/SegmentReporting 29 false false R30.htm 00000030 - Disclosure - Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details Narrative) Sheet http://misonix.com/role/BasisOfPresentationOrganizationAndBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details Narrative) Details http://misonix.com/role/BasisOfPresentationOrganizationAndBusinessAndSummaryOfSignificantAccountingPoliciesPolicies 30 false false R31.htm 00000031 - Disclosure - Inventories (Details) Sheet http://misonix.com/role/InventoriesDetails Inventories (Details) Details http://misonix.com/role/InventoriesTables 31 false false R32.htm 00000032 - Disclosure - Property, Plant and Equipment (Details Narrative) Sheet http://misonix.com/role/PropertyPlantAndEquipmentDetailsNarrative Property, Plant and Equipment (Details Narrative) Details http://misonix.com/role/PropertyPlantAndEquipment 32 false false R33.htm 00000033 - Disclosure - Patents (Details) Sheet http://misonix.com/role/PatentsDetails Patents (Details) Details http://misonix.com/role/PatentsTables 33 false false R34.htm 00000034 - Disclosure - Patents (Details Narrative) Sheet http://misonix.com/role/PatentsDetailsNarrative Patents (Details Narrative) Details http://misonix.com/role/PatentsTables 34 false false R35.htm 00000035 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://misonix.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://misonix.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables 35 false false R36.htm 00000036 - Disclosure - Stock-Based Compensation Plans (Details) Sheet http://misonix.com/role/Stock-basedCompensationPlansDetails Stock-Based Compensation Plans (Details) Details http://misonix.com/role/Stock-basedCompensationPlansTables 36 false false R37.htm 00000037 - Disclosure - Stock-Based Compensation Plans (Details 1) Sheet http://misonix.com/role/Stock-basedCompensationPlansDetails1 Stock-Based Compensation Plans (Details 1) Details http://misonix.com/role/Stock-basedCompensationPlansTables 37 false false R38.htm 00000038 - Disclosure - Stock-Based Compensation Plans (Details Narrative) Sheet http://misonix.com/role/Stock-basedCompensationPlansDetailsNarrative Stock-Based Compensation Plans (Details Narrative) Details http://misonix.com/role/Stock-basedCompensationPlansTables 38 false false R39.htm 00000039 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://misonix.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://misonix.com/role/CommitmentsAndContingencies 39 false false R40.htm 00000040 - Disclosure - Related Party Transactions (Details) Sheet http://misonix.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://misonix.com/role/RelatedPartyTransactionsTables 40 false false R41.htm 00000041 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://misonix.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://misonix.com/role/RelatedPartyTransactionsTables 41 false false R42.htm 00000042 - Disclosure - Income Taxes (Details Narrative) Sheet http://misonix.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://misonix.com/role/IncomeTaxes 42 false false R43.htm 00000043 - Disclosure - Licensing Agreements for Medical Technology (Details Narrative) Sheet http://misonix.com/role/LicensingAgreementsForMedicalTechnologyDetailsNarrative Licensing Agreements for Medical Technology (Details Narrative) Details http://misonix.com/role/LicensingAgreementsForMedicalTechnology 43 false false R44.htm 00000044 - Disclosure - Segment Reporting (Details) Sheet http://misonix.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://misonix.com/role/SegmentReportingTables 44 false false R45.htm 00000045 - Disclosure - Segment Reporting (Details Narrative) Sheet http://misonix.com/role/SegmentReportingDetailsNarrative Segment Reporting (Details Narrative) Details http://misonix.com/role/SegmentReportingTables 45 false false R46.htm 00000046 - Disclosure - Severance (Details Narrative) Sheet http://misonix.com/role/SeveranceDetailsNarrative Severance (Details Narrative) Details http://misonix.com/role/Severance 46 false false All Reports Book All Reports mson-20170331.xml mson-20170331.xsd mson-20170331_cal.xml mson-20170331_def.xml mson-20170331_lab.xml mson-20170331_pre.xml true true ZIP 65 0001615774-17-002030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-17-002030-xbrl.zip M4$L#!!0 ( #.*HDIHA]832W8 (HL!0 1 ;7-O;BTR,#$W,#,S,2YX M;6SLO6N3VT:2*/K]1MS_@*MC[]@1:(H 01*T9WRBU9*\VM6C5RW/['R:0 -% M$C8(T'ATB_/K;V96%5 039!@J\6]YQ=MT@"E9F5E:_*QU__[]=9H#VP./&C M\&\OC$[WA<9"-_+\/CX^=Q!SSKSIN--.NKN 5?_UZ M'P?^3_A_-5@X3'[ZFOA_>Z$\]-CK1/'DI=GM&B__]\/[.W?*9LZ5'R:I$[KL MA7P*WOM'W7/&:#1Z2=_*GR[]$A>7:_1>XM?W3E*\&0%<\_LE2.!;+\T?4'_< M?\F_+/W4K_WI@/_4ES_U6.5W"7,[D^CA)7P!OS>LJZYQU3/DSV,V7@GRX"5\ M*W_H)Y%E&L-U^/%?R >RY&KB.//\@;&3W-./Q1<(S* ,#'P31P%+:I^A;VH> M"J,PS&;U<'EI_#)=S-E+^-$5_(K%OIL_]_1#Y0< !ORX'CKZI@:Z68*'0SPP M Q*%_E=D:OSIL-N#'\KC@>ST4T),^YF-->+$GZ:T/_B2*_E YVOBO1!?XZI_ M>Y'XLWD ;/52OHH?%3<*4_8UU7SO;R_>QM&, S<$^-((7W;5[5T5Z^>/L3#U MTT7^:?ZY[^$W8Y_%&D')2M237';S[K]?_-*%_['MKM4S__JR^G"QW,O:]<1J M^J?ANZ3$6>O(A@7>QO%=Z1'Y> D!^*$BZFLZW MU\FGL-O[5\_X%\)W9L3E$BJMH9+\IATJ"6[L7G7[5]T1<2/];73_Y69)&LW^ M=1>%SHT3LP_,\UTG^,!F]RP^&C4+[F.3&5/(D'_E 3!?YX'O^BF'5?-\^"57 MC2!Y?WK/)D[PAN"]_NHG+W[!,_U3+9I_?5G[1A6:E_7@M'"DQ)XT.U)B\_9S MI+9DEG\)-?.O#W[HS[+9A85*T&RRJ*#@3Y^=<,+XDO*C$E$O#+NAKKU(MR,S MR^D9#$\SRXWOLN#.]<&W8M>A]X6YTYOH?>H]5ZY9C^^%?>K8IZ^PS^#"/B?* M/OUMV&>P3_8!;V5\D3BGQ3*'G]C>BWW9Z]Y7SCW8:6D< MA;Y+UKT3!(MWX8.3^ _LRY3%SMQGR7-E@XU1_[:DP84C3IHC#BDC9#CE5Q9- M /VI[[[VDS3V[[,4*/DVBID_"<^;&61PHQ[%<@!D S)\(Z+BPAAGQ!A[E1A/ MQS+>@[45)NQZ$C.&B(E0[;>B;22/?%G,V:?Q=1QC8!7?H^B=>A*U$] ]0VUW M]O&7"\M?6/XYQHR$)CG?&^Y#J,(:N7!F!#MQ9GS:Y(!##1A'\>)YR-';. )* MI8O; )CU.O3>_)GYG'.JF%]8 MIZ'-=V&=DV"=TU-7*V)JM[!"F#X39GD+YG3*WH,=[;T+P:2:^/'7Q/)CI^M&)O<)8E1^OQ/S9@G9(96*MIKJ6>/!HNO95Y@=8+/T\&'FC&)'\<1GULQ27 MQPQ-\X.74QBH?9W!Y]&]'SR7^^+-0XX;$./"8(TC$3%+:'/+Z0K7O MVXECN_7(4(W=>N2\O8K@9>ZNH]TJYC]W[MXC,YW<(=OC77.)3=L7R,9H1&N@ M%2S_OJ2E7]+2=Y?,!6OD2M3(=+6*%I M6.'"76?"7:?GV&\MNR[5M<>OKGVNDNO"6R?&6Z9WKL_G.'%O: MVHH/O?&)0 X]UMW]Y41<3L0W:'^LLVUOHMDL"I5$MW-G[KL4Z(?/8U9*N@#\ MYE$(_ZSDJB_A?6&=3>JE+NQR)'8YQR[X??]^/41_Y)0;EFL6+;V_G:S#_ MQL[\9>]/8^\/DSZRVD2\]CP?_0,GN'5\[UUXX\S]]+ED-&W($6MI<#$=-U$E M%S8Z,38ZLGJY\,/I\L.Q56L?T#](="'?>,1O0*=$Y(:Q>FGW'U M?%KS#K:A\X'Z1%^JU4Z@$NBLJM7VJHUJ?#_X>Z2,/;KD:%QR-$[,D14VSR[M%T^P_>(Y&9X7!CI!!CH]BWH#"73IHW?IH_=, MA>::BYH+SU]X_AG=*ZV1\Y?J_4OU_O,6\TNV\87E+RS_C5GS@JGOHM"Y<6(& M%#[_@/AJ!JI%\R(?&\K'"[-<)$N3=A(4%,=FR=X,Y#9X# Z:Y6^^SE&%E)4K M#^N#_1ZRA.6U\=$S\:+>A6XT8WERR_O(=>IZ VQ KWUKVO7[<.Q#<)I.U).5 MV,^-K2_L[T)GJ?>L^5?=;C M>V&?G[+0Y[SSV]WKI>V?43$@^\5/(LLTAC_!;^3+Y%?E)?!M*]Y_-P7[.5FY MA" "_6CK-0"^VQ7K>/X#\-TR;?'9C]F,CP]>9KL&-*C"6/=69='7+(S IGMJ MV:?I4EVW[L7R^Q(5-B#H+2SSQ);-X<^M-PQH5"=VY'OH"'_<_.TH![@(^,PF M9"V'Z4=GQC3!^I_9>)V)]N*7#^_N/GU\][_:NX\W?WVYZFW+J]V & [_5WH ML:__S18;+Z?*QI5O4Y=[';D9RB&,QVV\BM&]^A_^?O5Q];5?8@?G(MTM9O=1 ML#FQ@%;\O:7GZ^"])7GTADNKC1=0Y=W*MZG+7<.W'O[B;>!,-EYF[ 0)XRN4 M7J"^^2:+8_S83\#]_R=SXJ:X7,DD[G5O6^:L?[ @^.\P>@SO@/FCD'GODB0# MY;?ILA\CE;-6O&UYV;]'01:"0EJ\]0,6)ULN5WE+S;GA=/C,YE&<(@.!.YQM MOMH_420^];;E50F:&R#W)(HW/ZO7+E@2*-"9I]$;U*5+KZP[ 'RK.>.^A<\V M1_)_>F7F7WK3ZN60LYHMAG_7+9>_J68/BSXA7/5^RE),@$.!4%JWDNZGH>"F M+X3&UCSF8B0_^=N+=Q_?OOAEU#5[O;Y5VN$U:TG(\HM?)YF"Q8?_PFC0(BVD0)>%V2J8?<'_2[L3:/U M=@>R7/VW%L91UQKUS.$1022F6@>BW>L/NZ/NL4#L;T+%@=D;6J,=0>0):$)" M;Y0T4;K ME]D!J 9T&H 65_=MWS"MKRXX0>IM >EN-/TUBKQ'/PBV-QZ'70,47+&^?.-& M*S71W4\M1 $6!>62>-I>UG2[(&[^^G+MVYN#T$2X# 8#-,XW@D 2YS4;,Q#( MWA?G*__!>]^Y]P,_]1FRP<S'QDNV VL3]=\;60/5,M\: MU%V9R0 OQAKUJ_;G!LLT89@AVM5#X\E5A!%TZRS0 MK5EC&L7F_0M9>-K/+[ MMX"BB92PNN9P5&/I/0E$G#%/88.=J3$:63V[#$C]$MO!TH0F-CA:O6U :9$> M/;"_1RKG[[QZ$P%@CKI&SVJRN!01G^&[&_BOWX;,'/5Z-0*S;HFMP6D24S$' MYJ[0@&>9L18H8X#,&M8!4UE@.TB:L(HQL/M; *)PU YGI-_O#GJU;+KI>HW4 M8L_HVL9&RRG12HH)K0J,-CH-QL!4&'#-$MM"TX 8PY%E;P=,M5L32-=LEE$- M#W /WL1O3:$KNS< ):+ ]?1B.X+7@&170^">WL#8!;H5K1,5\F]_FH:6@<:[ MHO>>7&Q'\!JII'[7[)O&+M"5&ASO> ?0'8UZ?871EM_=F;:11X M+$YX,[7M ]%VMV?3M?7JES=1A6T ]/9&@@<;8 M%Z7J6J:O%81+#+PO3A/NBW@XP+NF2?=%Q1>/+9GIX7P3J"&>)HNV!W$3)[=-@%5S=A[#,E3G G\'C I>0N]ZAODZ_Z;/5UX" M;7^G,S"ZABK-VX+H()@VN2@:#0>F?0!$U]R6*$NJK][AZ/1'H\TN:E8LW3+P M#?;#MOL]]>YE=]@5P^_6B3_%5#WFD:U_RV+*B-J1]!! \B6NLW0:Q?Z_F;](>A_Q6JK6ZE% M:#8L*%L']]ZV!/NI1SMJI$!V\,>9/PDWBDKU!=S#HGPK)FP ^,OK] MT7X KQMYL#Z];3@<#O;$N'5S =:FF5KFP+ .* V*S]?ZP]5;=!-0+Z)DO33 MF+Z]BP*O#579MRT0Y+9JQI36V *$IO*[WQ_:O5)-PZ::L+,Y&+REX'NPJ-K@CRM,K"V%Z&L6VA*6ICQR91D#RZBERLZP M-.63*W"[@6/K^'5G6)HRRY5A&P/;K&/:U;!@:7.2HKCAOWD'8,3P22N^M7)7 MNVJ=7>!IRCBJ0M@'/$V9Q[#W"T]CFVC4')[/T<()T@7_T<Z;:M6 _4#5EJM$ Y.,V4%%MIOH# M_DB+)O85N !#14:M7W%W^!HK.A#G:GQDW_ U5GZ#D=4]''B-]6'?4@-;S<#; M*^.9=J]KJX5L^P&KN5SK8W>7?8/56*Z!$C!Z^X:JL5SK#_MJ]'!CJ I;#%>^ M 4C\,(.'A+&&$XS8.(H9_]T7YRM+WGQ-8R>*/3]TXL6[E,T2+*.#)^.(XF5M M&FU7!OJ!:KKQ'@$^,FV:"V33,"SUUNKYTJ:Q,NB;@V%W^"V0IK$BLOLCT[*. M0AI^G=):&,"P+*LD'(KW-UNY\=&S[5'IY&V[<&.^[G6');[>=N'F7&-9):Y9 MO7"9GU[[BG_V87M;OHUNWP\-CG?83X<&QSOZ MIT.#XPF"S6@ S[9\K6.8MME7;YE+2S1>O[%5-\3J_6Y;RZ]+F]VF\K9EZFQQ MN=2WK4&+U&EF@ Z&9;=E[?)/^S2W+'[E)+Z[7/2U*?>N*@"[ZG:,1IYG"90] M8/+D.5B'R4JA>@Q,GN39-9AT&[F\^\;D2?8_H3UY[0<9SDX_B9.B K,7; YZ M6O:.S4%/S-ZQ.>BIV1R;];;5_C0-;-'*R'@#F/:*W-;'Z1R0V_ITG0-R6Q^V MTT!N;UIK)_1:%"I[4V3G@N!Q3M\!$3S."5R'H/17;T7O"O';UJU"Q0. MD.UBX75'^X1L)VO-W"=DNUA>+=",M,(AN8P6W!JJ?7'8;E#MB[MV@VI?G%4+ MU3^8/YEB*Z,'$'P3QF=\?AJK(F]E3Y*-.&X%K+8YZ/4L)6VH(2![P&,]CZ[J MLS(C!: MQV&O)^- ..SU5!P(A[V>B,UPJ#66P4Q^,QXS%RSF#4SKUUD,;[^=.@EVG;^E MX:AMW);9MJ%6/.X)TB,2I'$%>_GZ\_D1I.F-W;/GD*9WB,?AD":=[C9JI+YI MK\ GM?U&D%6OKK> ;*FC8CN0->OSOLJ+J';*VP_5#@4;OIZWA!2L22Q)_48_ MLD?ZII5<#6NI8](F*^\3W&T'(PS409^G@\4.S>U'([/.R[;+E]UXK#8FW&D!4$ MVD1[.Y9<)+XOVI $X!\!@^Z-UM1=T*GO8ZHX\ M<5B:@-5$[-%WG^9TM0 '.G;]9,M;@JIPZ_:L4F_!ID <"HLMSTO?W%!PGP9R M.VBIKCE:&OZS!UPY%[?$CZOL--BUC57/<9'916BTCN6U]WO&VSHD7Z(5K$2O MNP?_R@.(L825_*[/[,_,3_R4W;'X :P$OO1GYD:3D-ZR/,!L2X$S -^EJUP4 M[1OF$Z51"R?^V)14!XU4YHNTP2C#0<]2O>\UR^T(6>,"$7-HV(-M0>,#4_/B M3U%'_HJ%K*5FIU< 7*EXXXDU6P"Q<66 .2@[%QN"2.:5_.U[!GPLQT"U4MQX MA0["FC6V!*,Q=08C-,F: L)IUU)W0LNN ,#?WG#AQCTJNC:V3%VS<"ER\ZHJ MR/:AH.I7VAZ>YOV#AWVCU-&]98":AL&Q$9%E[ ^>IE%HRQH8I0%Z^Z=/J_&7 MFF-@6I;:&F@/%%Y32;47C ;ER=V;8?21I3=.,KV-HP??8]ZKQ6\)RH.\\=VU M"U#P*?4U*>&-VNW;7VA2&(;PS5L]>,__==*.<) MWCH++(]$@\EU8_!Z5LULWUJ+#:LUK%M LC]\&BL""S23M7]\;F,V!Y]!ZE]A MB<'+J,<6GV+73JWYT#)[Z_#9!)+]X=/8>+%-TUS+;^W@@\T;PS2*6SHFH&I& M]F =V,J".T/7F*@#LS'^H]@E^Z.!.5P#[L;#?7>#N_%D M"Z/;'ZPC\\9PKS@(;_W0"=V#"!^K>FVV&TC[1[!YIW[#W!]^\!J7,8_2P YV ML_GDHJU N2NA=X(2+X]P>/NG&.>M?1KC"6HG,KJ4GO3TLNT N@$]OR;^3Z$? M_.U%"J[."^UE=>$-E69]'=\^FFKM!-#>L=NU75:KV*V0.X?;JT8 M []KGNQ M$_3X)*AA_ ^>SP_DW(]/CR&+DZD_ M!X9TX=_.I'P,5L]HO\UBMI3*8G14L;/QDFM-+K(,-O'WNE==(..(:$A_&]U_ MB1FV=U'HW#@Q^\ \W]THJZ)OK[%TZF%J!XNZ2YFML3#Z76MHV]M@P5,8:W]2 M;-RG,8WS%!-]>9RHWB#>87-J.:W;ZV +.'Y-%EJLT=;Y;A>5TT>W0"B M%G:J;:Q6;55_IZTR&NZ5>3CIL"E$5=D@!N0(1-N -[^;_>"'_BR;;7(;VR^+ MN#)0S4%>([K>^R[=<4QBQE )")C%MX!(&D>A[Q+L3A L0%TX">S]ERF8I7/P M$S9!Q^[9EKT\L6EK?.KFW!\2GU'/-*T6]ZSC:JVB];^"6;Z&J-G2E-E# =0,\$-RY/@M=O%O]PMSI3?0^]391 MQ0,<1Z2DU-:!L#6OT60#0@A-W'"7!;P_ 6I[E/F?=K%'G;$P).NS6TZBA1>O\64#1C":/4<* A M$.1";4V"@3&R[%IFH/%16M_&B6) B2E<2%C^P[=$V3&# H5T# MP=(:6T+3@!RP_7VC6R<4G@1&K4&!OP.VI[*<@0WNEI*5LLFZ;<':-%@ZLLV1 MO:).9]^PKO&)?V4AWKE$\2:62+_7JU3*' Z'II4!9A_8MW\T>C>J&NA9 .R. ML*[,6'F3I+!2RKS?$C;.@O=^528\S23YR1<\\LM_!.G/\_^8I#_C'V-XEY:D MBX#][07^_9-F=.>I]L6?P4(?V:/V.9HYHKPYHAM323XS;AI46CI O]SV_[D!M,6" M+<&X)E!4 V-O-QC1"$@9DMBKAAE5)A59Q1\15#YPZ,LC"Q[8!P!_6JN9JN[( M+6PHV.,;1=Y,M2-6*Q#NAK9XX3^!K;\\1NUB:QC=X:B[+;IER-K# M7?"/K#;P1-A:P_1ME,7M(@J[J:J G2!K#TUXI&4T3;N5[43(6D'S>@SN[7YP M[1F#@6'OB&P)OLTQ;J[/ZO'[Y=88_G,3%%;K"A6W[:^?FY/?[@[4E/7U8.P. M=)W^;0[T8&2/AH<#>ET]:0/5.[2'!P2Z[AY@"Z![756!-@2:U[+=.@L)@.T" U_ )]N+QDP2X:E=B6.:H#I3Z5;8'J0%QK-[2S41CB'#6.*/? M.<%;MCO+F*;=5RV,]
U; MP-"$'MU!.=RQ#@3*;I&MW^ M4-F/]
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
1"I3?7G@A:CO>GK')4DF4OK\8DEIS1]0O/. XE[RH/,.*&ZY6EYMAHR1C;56V&;4Z;$Z/-,B.KGD!55@X[F MNDA27K:G?1Z"]1Y+3*B++&B@UZJ2RZ=F@E]C-DU#7=N[RS:@>1AL=ZM+D*B[ M>(@CNZ1X:CC^@#ICNV6W1[$N"OPKP.)9"./U7^TQU=5;$@2N_MY283/P"P>& M@ZO#�VW.X%T1Q8).)Z,! *<$; >M- TUV'*^C"F"7BS# 0>[S(7S?43\": MG1I.@[Q]E.L\TW" &$A>$WSES:W.$.>!:&#>0=?AH#&17 M@LN^ VZL[O(=H\H4[/R=>?+^1?2E*=51"<\3_6I(LSC'KAB*"L-A;-MQL5T> M*,I1%NG(U>-8"A'6:!CUXU2*$^?NI$-BWWUA*(;Y=BH\>K& MT31AT]ZA#/7A[FWH=[[L,]]SIE!F7W@,/LYHOQH#)'ZIG]6+8R7+<+!LS&WE2##TIC4TBKO+& M6V3O3>MX;8ZU]G?)KY)@5-5N;Q1,S5U!DK<4(A:NN&O8)UALHL M!U*0W4@Q91F57GC.'*:^MG[85\_=YS^S)&B@=EIL<8L:CU:TVMIC7P*[HV3F MG&!)Y^5S0!=U5>?V M;%2=U6D^_?]8/?WG(QWKD2;EH;+*3#1.^VMZKZ=E$F]9J-..3T2 M2@/R5ZBL#H%MQ\6\/]9D'5?A+SW"=;Q8-RDH/WKQ9'#N<:E+Q&GG5CI_RI[D MTD73SR5C%U'"E(HFMXI[PW7T$]&]F#THV_5:_!=(4;CG+"6CYG=!PB[VC/I M*\G?,SDW/&@PY#>QO3;#Z>2@(!%2QKYL;\GG7X62O-Y9+'8X7[9]'-M317_* M-,/VAO7TE#_S0&TM$;1T\]/8CKGQZ&@39/C7CX SQV'SH>.GCH>.R>'^V/$V MCAW7N8)?ITF<>%' HYE.>S@74O]Q@%G)\KW] <,5FY$OD'4>KU)SL. G\(^ M0PRL(8.IXR94G=UV3TQR$=PEGDSP?;K;BN>K:IC$%]%-QI3EV8I!/H9]Y!B5 M-AO@(C*SZAW9A=J*JMUG*G6]L]Q:-%-Q]L?KY1Z529_'C:]OKP+OW,?"/ASL M5ILZ"WO\EUG;"EI)=LIXHO9.*W,:;N)K_!AVZ,*H)CX#7.ZZ_"77Y8C-]#9Y M_+JLSOL\?[=V![K<^#'LX(Y1Z;(!KKTN8QZM?H._,#_<4^1CTN1&"?9RO#J+ MWH N_Y7%RB9U=>SEG9;0ORIV8]ECR@.K.)P"[%"=4>F]*[![8]@ Z&^,SQZU M '5LY8PM3RF!&H!8[B#0K: CEKP1FR@P4^,M@8X4@*U@3%<;J&O M IVT8"0V\$;.UPXW!X=CN 0;Q0E[?]G@YI/&L:!MZ8*:U1ANY'#-JA\-^4/; MFG[F-EE<1'$BTVSQSFH'W#]Z42'CHR#@^@OG/\:U1C_X MOKF]UT642![%W,\RC7:RVZI^$JJH@]V_8>O48%NL9G#_(-<6([(!AS/&1WJW M>..R@OW1 K!Q+$GO:#:3603BKJQD"Y*@-D3O8H^D#6VM'+U;&+U\9LNS1S]W MS6LF\1K2/K_YC;V7-,R1;/^ TG"(C?T!I6P]N5=?,3^15&DV(ME7**?QS%'W MJZDU.U&@ER3(6TC#?(V&#C3J;V\7@2;^2;R;=#9_"L6"L5+*J>T-)4,7\ADX M6YA%12>L@J/A2;Q5^WG)]=X^(]2&;4MS(*Z#>9IWB*M18#0PO4L?8O:/5+%X M]JP7+^OBV]J!QA0,VP*U\5 J,D$+$^NJVMZ%""YF/;,#1&JEJ]!GFPE;FJ/G MVMGTS(P*Q>FL.)O>>#)9W*L9/58G4>V=.EZ4_V*>X5S&(&)10B M8-HFP*:V-,!Q5TD#<*1FP9-'SJ9GK\Q/M>_Q>CKE/I.VN=#8"7MOV*YQ%4P MK-.8$)MWNZ['<_02A^#'%\W\TL!D==QC\EGI33/)5R)ZSJ]4]*DCOM>/1)3_ MKMVO5R+Y.TMNF2]F$?]G<GA"J,CN%XXUK8!Z8?BYD\2O= MSE!B?]=TH!<91-=)(T TE'-]I^3XC, Z10)4_*J?3Z!7&G1:&?L4*R%MZ1*W MD/V?#E%8%4RTO072VU?02_YMMYO:3K@C5QM(+GOVQU,EXU55_N$BH)P)0:_1 M-[CR;0?16]1/P@6=A[N_P]&SMF+,8ZY?T677L!$6N!3.RMB&>';+^D5T?_O@ M6S6@T+>=XEI>"![ D)KT1']KF$]ANQ_M"C(<[R/2#.M2OANM@9"!72T00Z/@ M\ RI;5M,GRN_RF;Y$<717#\*;%*N(;^*7[H/KDS#2Y_H3)43F1O"1>1+IMJ= MLOR_ \U*YD_BUZ_;R10$D3N1DYWIM8XK]I+]R1A^#NN/7X$-O-UUDDC/9ZH= M9PDI[9[S),^4B)2N1]I#QB*?,V"2T)=JDE!IQ(D7Z42ATIC$#:)_P0"_PBG/!S(\43D\E"1U,G.G?T'RE_RE=[>R0RJ/.( M< +Q0R-EJ)542*PRJ#,-W!ST$PHFN5CFXU1)0,WKML"]:COL6 H'':Q@T\SQ M0 ?*/#9P19PB]"A-Q%P\\)#%K3+774$]L<,/.J YHW2J4V=*<6Q$8X8#K4Q&/FCDS+20:%N++-UH8 30/1A@I-:=KRQBT@NUZ0=S'G%] MBM#G4UT_)(J9;3D"=L<.M0'I904])\GT.3W&S/]^)I[?!XQK'#_K'S1\GTOP MJ5_]=LEF7GBF3H.MJ32J5:T1#6,R3WA-=/>9# .5MK1I/]FUSF27N^HL2$6W'3DA/[,,_[%+1 M00@T#.921+-[)N95P"%)1]* (5 MOQK]4(1]Y: ^*PULD;B[N=&R9,'S%XYK=80V_D#KA#4PN+^NF9' MUS6]W$?OKVN&O:XY>GH*.0N.N;A+Y8S[7FB\J&EOCC8M *YH;$P2.5BG#VJ^ MXIY7@FWI,H;)P\X%C3*();)TQ>'K:6DO8*T+"^A+!"N;_C7X M1FR<$=GK\&>EAC>AYV>Z:-_R-+=']R6"U;"V$S()@,;L5SC9SA73I1T>-UT_ M&[J,Y8K9RC4-<(Y\7U\:Q+?,9TJ5U%2^2>U)*K54VJ$"#X!]N@ CYRB2<>?, M61S-YH2YSX<=/,XTLN7VON>][WGO>][[GO>^Y[WOFT?30(XF M['>']HZFO:,)?YI[TXZF,G.I)D_](ZMSD]>_N8A*S,*LS3[*6-Q1761##E6E MA#Z[83*C'(1@I0>Z^76 JY%I&M#<2.$S%L3:R:GU2,FM(BPO M"9;R:%:D6ID?GG(8 WL5=%7=F_V5+00@T+AAR,A=%++4AUJ?2;C07 M!LT,CCND^([--.NW[$E(72#*6+/B<]6Q5?2>K+J3*%51Y)RO& OM=I1=IQ&NOZGG&A7+$E6L[<;8S8-'-"PQM5T&0-D-ML1@P% MDX950=EDA$3HVUFSO"RCM^R-H=T\_*1SZ#6=&/=2LJ^O=F/6TOB2\_9+"#[.7K M>CL*/H=Q>=]:!+GWN9$\LQ+VN>U3\?>I^%0B,3K(W0K<+I[?LF?8KU^N&F&2 MO8%X2B?'?YU33A'Y3RCC#N0R />WU M$-OJ+J^!XJ@V7LX[BJ+4"X_5M^^\T).+%JPL?;"/\:#0*1#?-!:G+&O\.B-5 MOQQN?66IK3VVV $0 @ %Z=@ M;7-O;BTR,#$W,#,S,2YX&UL4$L! A0# M% @ ,XJB2IM'4.JH& B* ! !4 ( !KY$ &US;VXM M,C Q-S S,S%?9&5F+GAM;%!+ 0(4 Q0 ( #.*HDHJ*2::(4, $S- P 5 M " 8JJ !M[0 ;7-O;BTR E,#$W,#,S,5]P&UL4$L%!@ & 8 B@$ !P; 0 $! end

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	Apr. 28, 2017
Document And Entity Information
Entity Registrant Name	MISONIX INC
Entity Central Index Key	0000880432
Document Type	10-Q
Trading Symbol	MSON
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		9,023,354
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

Consolidated Balance Sheets (unaudited) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 11,856,503	$ 9,049,327
Accounts receivable, less allowance for doubtful accounts of $96,868 and $96,868, respectively	4,357,156	3,869,427
Inventories, net	4,909,415	5,822,935
Prepaid expenses and other current assets	664,249	530,564
Total current assets	21,787,323	19,272,253
Property, plant and equipment, net of accumulated amortization and depreciation of $7,610,152 and $6,976,282, respectively	3,413,116	2,492,815
Patents, net of accumulated amortization of $965,996 and $885,394, respectively	710,070	604,916
Goodwill	1,701,094	1,701,094
Intangible and other assets	300,341	266,603
Deferred income tax	3,581,551	3,394,690
Total assets	31,493,495	27,732,371
Current liabilities:
Accounts payable	1,433,608	1,402,797
Accrued expenses and other current liabilities	1,994,387	1,887,337
Total current liabilities	3,427,995	3,290,134
Deferred lease liability	9,331	9,262
Deferred income	17,737	31,685
Total liabilities	3,455,063	3,331,081
Commitments and contingencies (Footnote 9)
Shareholders' equity:
Common stock, .01 par value-shares authorized 20,000,000; 9,162,203 and 7,948,234 shares issued and 9,023,354 and 7,809,385 outstanding in each period, respectively	91,622	79,482
Additional paid-in capital	37,410,034	32,502,521
Accumulated deficit	(8,363,872)	(7,081,361)
Treasury stock, at cost, 138,849 shares in each period	(1,099,352)	(1,099,352)
Total shareholders' equity	28,038,432	24,401,290
Total liabilities and shareholders' equity	$ 31,493,495	$ 27,732,371

Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts (in dollars)	$ 96,868	$ 96,868
Accumulated amortization and depreciation (in dollars)	7,610,152	6,976,282
Patents, Accumulated amortization (in dollars)	$ 965,996	$ 885,394
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	9,162,203	7,948,234
Common stock, shares outstanding	9,023,354	7,809,385
Treasury stock, shares	138,849	138,849

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Net sales	$ 7,177,763	$ 5,426,147	$ 19,379,768	$ 16,716,487
Cost of goods sold, exclusive of depreciation from consigned product	2,112,099	1,859,749	5,842,778	5,578,349
Gross profit	5,065,664	3,566,398	13,536,990	11,138,138
Operating expenses:
Selling expenses	3,587,859	3,319,385	10,184,680	8,967,352
General and administrative expenses	2,484,962	1,515,559	6,504,202	4,994,569
Research and development expenses	465,863	548,278	1,398,311	1,340,339
Total operating expenses	6,538,684	5,383,222	18,087,193	15,302,260
Loss from operations	(1,473,020)	(1,816,824)	(4,550,203)	(4,164,122)
Other income (expense):
Interest income	18	19	56	63
Royalty income and license fees	953,235	963,025	2,846,351	2,969,557
Other	(6,940)	(5,464)	(15,576)	(16,898)
Total other income	946,313	957,580	2,830,831	2,952,722
Loss from operations before income taxes	(526,707)	(859,244)	(1,719,372)	(1,211,400)
Income tax benefit	(219,000)	(15,000)	(275,000)	(322,000)
Loss from continuing operations	(307,707)	(844,244)	(1,444,372)	(889,400)
Discontinued operations:
Income from discontinued operations net of tax expense of $88,139 and $85,000 respectively	161,861	165,000	161,861	165,000
Net income from discontinied operations	161,861	165,000	161,861	165,000
Net loss from total operations	$ (145,846)	$ (679,244)	$ (1,282,511)	$ (724,400)
Net loss per share - Basic continuing Operations (in dollars per share)	$ (0.04)	$ (0.11)	$ (0.17)	$ (0.11)
Net loss per share - Diluted continuing operations (in dollars per share)	(0.04)	(0.11)	(0.17)	(0.11)
Net income per share - Basic discontinued operations (in dollars per share)	0.02	0.02	0.02	0.02
Net income per share - Diluted discontinued operations (in dollars per share)	0.02	0.02	0.02	0.02
Net loss per share - Basic (in dollars per share)	(0.02)	(0.09)	(0.16)	(0.09)
Net loss per share - Diluted (in dollars per share)	$ (0.02)	$ (0.09)	$ (0.16)	$ (0.09)
Weighted average shares - Basic (in shares)	8,613,354	7,789,174	8,263,343	7,772,761
Weighted average shares - Diluted (in shares)	8,613,354	7,789,174	8,263,343	7,772,761

Consolidated Statement of Shareholders' Equity (Unaudited) - 9 months ended Mar. 31, 2017 - USD ($)	Common Stock [Member]	Treasury Stock [Member]	Additional paid-in capital [Member]	Accumulated deficit [Member]	Total
Balance at beginning at Jun. 30, 2016	$ 79,482	$ (1,099,352)	$ 32,502,521	$ (7,081,361)	$ 24,401,290
Balance at beginning (in shares) at Jun. 30, 2016	7,948,234	(138,849)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss				(1,282,511)	(1,282,511)
Sale of common stock	$ 7,615		3,992,385		4,000,000
Sale of common stock (in shares)	761,469
Issuance of restricted stock	$ 4,000		(4,000)
Issuance of restricted stock (in shares)	400,000
Proceeds from exercise of options	$ 525		302,922		$ 303,447
Proceeds from exercise of options (in shares)	52,500				(52,500)
Stock-based compensation			616,206		$ 616,206
Balance at end at Mar. 31, 2017	$ 91,622	$ (1,099,352)	$ 37,410,034	$ (8,363,872)	$ 28,038,432
Balance at end (in shares) at Mar. 31, 2017	9,162,203	(138,849)

Consolidated Statement of Shareholders' Equity (Parenthetical) - $ / shares	Mar. 31, 2017	Jun. 30, 2016
Statement of Stockholders' Equity [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities
Net loss from continuing operations	$ (1,444,372)	$ (889,400)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization and other non-cash items	763,434	1,271,864
Deferred income tax benefit	(186,861)	(260,000)
Stock-based compensation	616,206	1,175,165
Deferred income	(13,948)	(20,852)
Deferred lease liability	69	6,947
Changes in operating assets and liabilities:
Accounts receivable	(487,729)	379,689
Inventories	(449,986)	(2,623,620)
Prepaid expenses and other assets	(167,423)	(282,221)
Accounts payable and accrued expenses	137,861	141,624
Net cash used in operating activities	(1,232,749)	(1,100,804)
Investing activities
Acquisition of property, plant and equipment, net of disposals	(239,627)	(410,561)
Acquisition of patents	(185,756)	(71,541)
Net cash used in investing activities	(425,383)	(482,102)
Financing activities
Proceeds from the sale of common stock	4,000,000
Proceeds from exercise of stock options	303,447	151,247
Net cash provided by financing activities	4,303,447	151,247
Cash flows from discontinued operations
Net cash provided by investing activities	161,861	165,000
Net cash provided by discontinued operations	161,861	165,000
Net increase / (decrease) in cash and cash equivalents	2,807,176	(1,266,659)
Cash and cash equivalents at beginning of period	9,049,327	9,623,749
Cash and cash equivalents at end of period	11,856,503	8,357,090
Supplemental disclosure of cash flow information:
Cash paid for income taxes	9,866	141,120
Capitalization of consigned product	$ 1,363,506	$ 1,017,506

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These consolidated financial statements of Misonix, Inc. (“Misonix” or the “Company”) include the accounts of Misonix and its 100% owned subsidiaries. All significant intercompany balances and transactions have been eliminated. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. As such, they should be read with reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which provides a more complete explanation of the Company’s accounting policies, financial position, operating results, business properties and other matters. In the opinion of management, these financial statements reflect all adjustments considered necessary for a fair statement of interim results.
Reclassifications	Reclassifications Certain expenses on the Statement of Operations have been reclassified to be consistent with the current year presentation. Historically, the Company had recorded stock compensation expense and bonus expense predominantly within general and administrative expenses. The Company has reclassified the prior years’ presentation to allocate certain of these costs to cost of goods sold, selling expenses and research and development expenses, which is consistent with the classification being used in fiscal 2017. This reclassification had no impact on the Company’s presentation of operating income (loss) and the gross profit impact was not material.
Organization and Business	Organization and Business Misonix designs, manufactures, develops and markets therapeutic ultrasonic devices. These products are used for precise bone sculpting, removal of soft tumors, and tissue debridement in the fields of orthopedic surgery, plastic surgery, neurosurgery, podiatry and vascular surgery. In the United States, the Company sells its products through a network of commissioned agents assisted by Company personnel. Outside of the United States, the Company sells to distributors who then resell the product to hospitals. The Company operates as one business segment.
High Intensity Focused Ultrasound Technology	High Intensity Focused Ultrasound Technology The Company sold its rights to the high intensity focused ultrasound technology to SonaCare Medical, LLC (“SonaCare”) in May 2010. The Company may receive up to approximately $5.8 million in payment for the sale. SonaCare will pay the Company 7% of the gross revenues received from its sales of the (i) prostate product in Europe and (ii) kidney and liver products worldwide, until the Company has received payments of $3 million, and thereafter 5% of the gross revenues, up to an aggregate payment of $5.8 million, all subject to a minimum annual royalty of $250,000. Cumulative payments through March 31, 2017 were $1,504,788. Payments are generally received once per year, in the Company’s third fiscal quarter. For the three months ended March 31, 2017 and 2016, the Company received a royalty of $250,000 in each quarter, which has been recorded in discontinued operations.
Major Customers and Concentration of Credit Risk	Major Customers and Concentration of Credit Risk Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. (“Cicel”) of $0 and $1,337,277 for the nine months ended March 31, 2017 and 2016, respectively, representing 8.0% of sales for 2016. There were no accounts receivable from Cicel at March 31, 2017 and June 30, 2016. The Company terminated its agreement with Cicel in the first quarter of fiscal 2017. For the three months ended March 31, 2017, one international distributor accounted for approximately 10% of sales for the quarter. In addition, this same customer had outstanding accounts receivable at March 31, 2017 of $369,463. Total royalties from Medtronic Minimally Invasive Therapies (“MMIT”) related to their sales of the Company’s ultrasonic cutting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $2,838,487 and $2,930,240, for the nine months ended March 31, 2017 and 2016, respectively. Accounts receivable from MMIT royalties were approximately $953,000 and $973,000 at March 31, 2017 and June 30, 2016, respectively. The license agreement with MMIT expires in August 2017. At March 31, 2017 and June 30, 2016, the Company’s accounts receivable with customers outside the United States were approximately $762,000 and $768,000, respectively, none of which is over 90 days.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for, but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and related valuation allowances, and stock-based compensation. Actual results could differ from those estimates.
Loss per Common Share	Loss per Common Share Diluted EPS for the three and nine months ended March 31, 2017 and March 31, 2016 as presented is the same as basic EPS as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. Accordingly, excluded from the calculation of diluted EPS are outstanding options to purchase 145,750 and 512,750 shares of common stock for the three and nine months ended March 31, 2017, and options to purchase 844,250 and 486,000 shares of common stock for the three and nine months ended March 31, 2016.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. Under the new standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those periods. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will apply this guidance to applicable impairment tests after January 1, 2017. In February 2016, the FASB issued guidance on lease accounting requiring lessees to recognize a right-of-use asset and a lease liability for long-term leases. The liability will be equal to the present value of lease payments. This guidance must be applied using a modified retrospective transition approach to all annual and interim periods presented and is effective for the Company beginning in fiscal 2019. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements. In November 2015, the FASB issued ASU 2015-17 “Balance Sheet Classification of Deferred Taxes (Topic740)”. The amendments in this ASU require deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments eliminate the guidance in Topic 740 that requires an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount in a classified statement of financial position. The Company adopted ASU 2015-17 as of March 31, 2016 on a prospective basis in order to simplify the balance sheet classification of deferred taxes. In May 2014, the FASB issued guidance on revenue from contracts with customers. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved, in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. This guidance permits the use of either the retrospective or cumulative effect transition method and is effective for the Company beginning in 2019; early adoption is permitted beginning in 2018. The Company has not yet selected a transition method and is currently evaluating the impact of the guidance on the Company's financial condition, results of operations and related disclosures. The FASB has also issued the following additional guidance clarifying certain issues on revenue from contracts with customers: Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients and Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing. The Company is currently in the early stages of evaluating this guidance to determine the impact it will have on its financial statements. There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	May 10, 2010	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016
Ownership percentage		100.00%		100.00%
Sales from continuing operations		$ 7,177,763	$ 5,426,147	$ 19,379,768	$ 16,716,487
Excluded from the calculation of Diluted EPS (in shares)		145,750	844,250	512,750	486,000
International [Member]
Sales from continuing operations				$ 7,360,665	$ 7,391,559
Accounts receivable		$ 762,000		762,000		$ 768,000
SonaCare Medical, LLC ("SonaCare") [Member]
Proceeds from sale of intangible assets	$ 5,800,000			1,504,788
Earn-out percentage	7.00%
Proceeds from sale of intangible assets	$ 3,000,000
Earn-out percentage	5.00%
Proceeds from sale of intangible assets	$ 5,800,000
Royalty revenue		$ 250,000	$ 250,000
SonaCare Medical, LLC ("SonaCare") [Member] \| Minimum [Member]
Royalty revenue	$ 250,000
Cicel (Beijing) Science and Tech Co. Ltd. ("Cicel") [Member]
Sales from continuing operations				0	$ 1,337,277
Percentage of continuing operations		10.00%			8.00%
Accounts receivable		$ 369,463		369,463		0
Medtronic Minimally Invasive Therapies ("MMIT") [Member]
Accounts receivable		953,000		953,000		$ 973,000
Medtronic Minimally Invasive Therapies ("MMIT") [Member] \| License Agreement [Member]
Royalty revenue		$ 953,235	$ 956,947	$ 2,838,487	$ 2,932,240

Inventories (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Inventory Disclosure [Abstract]
Raw material	$ 2,481,557	$ 3,102,175
Work-in-process	708,593	854,631
Finished goods	3,004,743	3,101,234
Inventory, gross	6,194,893	7,058,040
Less valuation reserve	1,285,478	1,235,105
Inventory, net	$ 4,909,415	$ 5,822,935

Patents (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Total	$ 710,070	$ 604,916
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
2017	28,239
2018	110,790
2019	102,484
2020	79,055
2021	72,884
Thereafter	316,618
Total	$ 710,070	$ 604,916

Patents (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Patents (Details Narrative) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016
Patents totaled	$ 710,070		$ 710,070		$ 604,916
Patents [Member]
Intangible assets estimated useful lives			17 years
Patents totaled	710,070		$ 710,070		$ 604,916
Amortization expense	$ 27,877	$ 23,090	$ 80,602	$ 69,897

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Payables and Accruals [Abstract]
Accrued payroll, payroll taxes and vacation	$ 676,882	$ 648,705
Accrued bonus	300,000	300,000
Accrued commissions	429,000	433,000
Professional fees	228,584	256,130
Deferred income	29,491	20,655
Severance	99,859
Other	230,571	228,847
Accrued expenses and other current liabilities	$ 1,994,387	$ 1,887,337

Stock-Based Compensation Plans (Details)	9 Months Ended
Stock-Based Compensation Plans (Details)	Mar. 31, 2017	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rates	1.80%	1.71%
Expected option life in years	6 years 3 months	6 years 3 months
Expected stock price volatility	54.68%	55.41%
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation Plans (Details 1)	9 Months Ended
Stock-Based Compensation Plans (Details 1)	Mar. 31, 2017 USD ($) $ / shares shares
Outstanding Shares [Roll Forward]
Outstanding at beginning \| shares	1,790,224
Granted \| shares	327,500
Excercised \| shares	(52,500)
Forfeited \| shares	(376,625)
Expired \| shares	(2,700)
Outstanding at ending \| shares	1,685,899
Vested and exercisable at ending \| shares	980,774
Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning \| $ / shares	$ 6.38
Granted \| $ / shares	8.34
Excercised \| $ / shares	5.78
Forfeited \| $ / shares	8.24
Expired \| $ / shares	3.45
Outstanding at ending \| $ / shares	6.37
Vested and exercisable at ending \| $ / shares	$ 4.63
Aggregate Intrinsic Value [Roll Forward]
Outstanding at beginning \| $	$ 1,675,072
Outstanding at ending \| $	9,324,182
Vested and exercisable at ending \| $	$ 7,097,409

Stock-Based Compensation Plans (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 15, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2017
Compensation cost		$ 532,341	$ 446,172	$ 616,206	$ 1,175,165
Unrecognized compensation cost		2,771,938		$ 2,771,938
Period of recognition				2 years 9 months 18 days
Weighted average fair value at date of grant (in dollars per share)				$ 4.46	$ 4.23
Number of shares granted				327,500
Fair value of shares vested				$ 1,055,434
Number of non-vested stock options				224,250
Weighted-average grant-date fair value of non-vested stock options (in dollars per share)				$ 4.71
Amount of non-vested options forfeited				$ 616,239
Modified of certain stock options				$ 81,765
Subsequent Event [Member]
Number of non-vested stock options						976,875
Weighted-average grant-date fair value of non-vested stock options (in dollars per share)						$ 4.81
Stock Options [Member]
Option Expiration period				10 years
Option vesting period				4 years
Restricted Stock [Member] \| Chief Executive Officer [Member]
Compensation cost		$ 224,498		$ 265,063
Option vesting period	5 years
Fair value of shares vested	$ 3,400,000
Number of stock issued	400,000

Related Party Transactions (Details Narrative) - Mr. Stavros G. Vizirgianakis [Member] - Private Placement [Member]	Oct. 25, 2016 USD ($) $ / shares shares
Number of shares sold \| shares	761,469
Share price (in dollars per share) \| $ / shares	$ 5.253
Proceeds from stock sold \| $	$ 4,000,000

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Details Narrative) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income tax benefit from continuing operations	$ 219,000	$ 15,000	$ 275,000	$ 322,000
Effective rate			16.00%	26.60%

Licensing Agreements for Medical Technology (Details Narrative) - License Agreement [Member] - Medtronic Minimally Invasive Therapies ("MMIT") [Member] - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 1996	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Agreement expiration date	2017-08
Percentage royalties on sales of product	5.00%
Revenues for royalties		$ 953,235	$ 956,947	$ 2,838,487	$ 2,932,240

Segment Reporting (Details) - USD ($)	3 Months Ended		9 Months Ended
Segment Reporting (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Total	$ 7,177,763	$ 5,426,147	$ 19,379,768	$ 16,716,487
Domestic [Member]
Total			12,019,103	9,324,928
International [Member]
Total			$ 7,360,665	$ 7,391,559

Segment Reporting (Details Narrative)	9 Months Ended
Segment Reporting (Details Narrative)	Mar. 31, 2017 N
Segment Reporting [Abstract]
Number of operating segment	1

Severance (Details Narrative) - Mr. Michael A. McManus, Jr. [Member] - Retirement Agreement and General Release [Member] - USD ($)		3 Months Ended	9 Months Ended
	Aug. 26, 2016	Sep. 30, 2016	Mar. 31, 2017
Description of annual base salary	the Company agreed to (i) pay Mr. McManus’ salary through June 30, 2017 at the then current level; (ii) continue to pay premiums for Mr. McManus’ and his dependents’ coverage under the Company’s medical, dental, vision, hospitalization, long term care and life insurance coverage through June 30, 2017 at the then current levels upon timely election by Mr. McManus under the law informally known as COBRA; and (iii) extend the exercisability of previously granted and then currently vested options to purchase shares of Common Stock through June 30, 2017.
Non-cash compensation expense			$ 61,000
Compensation expense to forfeiture of unvested stock options			$ 596,000
Accrue benefits under employment agreement		$ 330,000